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Abstract
The Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority (GMO Panel)
previously assessed the two single events combined to produce soybean 305423 9 40-3-2 and did not
identify safety concerns. No new data on the single events affecting the original conclusions were
identiﬁed. Based on the molecular, agronomic, phenotypic and compositional characteristics, the
combination of soybean events 305423 and 40-3-2 in the two-event stack soybean did not raise
concerns regarding food and feed safety or nutrition. The combination of the newly expressed proteins
in the two-event stack soybean did not raise human or animal health concerns. No compositional
differences requiring further assessment were identiﬁed between soybean 305423 9 40-3-2, the
non-GM comparator, additional comparators and the non-GM commercial soybean reference varieties,
except for the altered fatty acid proﬁle (consistent with the intended trait). Nutritional assessment of
food products from soybean 305423 9 40-3-2 identiﬁed no concerns for human health and nutrition.
There are no concerns regarding the use of feedingstuffs from defatted toasted soybean
305423 9 40-3-2 meal. There are no indications of an increased likelihood of establishment and spread
of occasional feral soybean plants, unless these are exposed to acetolactate-synthase-inhibiting or
glyphosate-containing herbicides. Risks associated with the unlikely, but theoretically possible, horizontal
transfer of recombinant genes from soybean 305423 9 40-3-2 to bacteria were not identiﬁed.
Considering the scope of the application, interactions with biotic and abiotic environments are not
considered a relevant issue. The post-market environmental monitoring plan and reporting intervals are
in line with the intended uses of soybean 305423 9 40-3-2. The GMO Panel is of the opinion that
soybean 305423 9 40-3-2 is as safe as the non-GM comparator and non-GM commercial soybean
varieties with respect to potential effects on human and animal health and environment in the context of
its scope. The GMO panel recommends a post-market monitoring plan.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following the submission of application EFSA-GMO-NL-2007-47 under Regulation (EC) No 1829/2003
from Pioneer, the Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority (GMO
Panel) was asked to deliver a scientiﬁc opinion on the safety of the herbicide-tolerant, high-oleic acid,
genetically modiﬁed (GM) soybean 305423 9 40-3-2 (Unique Identiﬁer DP-3Ø5423-1xMON-Ø4Ø32-6).
The scope of application EFSA-GMO-NL-2007-47 is for food and feed uses, import and processing, but
excludes cultivation within the European Union (EU).
The single soybean events 305423 (conferring the high-oleic acid phenotype and expressing
Glycine max herbicide-resistant ALS (GM-HRA)) and 40-3-2 (expressing CP4 EPSPS) were assessed
previously by EFSA and no concerns were identiﬁed for human and animal health or environmental
safety. No safety issue was identiﬁed by updated bioinformatic analyses, nor reported by the applicant
concerning the two single soybean events, since the publication of the respective scientiﬁc opinions.
Consequently, the GMO Panel considers that the previous conclusions on the safety of the single
soybean events remain valid.
The two-event stack soybean 305423 9 40-3-2 was produced by conventional crossing to produce
high-oleic acid phenotype soybean tolerant to acetolactate-synthase (ALS)-inhibiting herbicides and
glyphosate-based herbicides. The GMO Panel evaluated soybean 305423 9 40-3-2 with reference to
the scope of the application and the appropriate principles described in its guidelines for the risk
assessment of GM plants and derived food and feed, the environmental risk assessment (ERA) of GM
plants and the post-market environmental monitoring (PMEM) of GM plants. The scientiﬁc evaluation of
the risk assessment included molecular characterisation of the inserted DNA and analysis of the
expression of the corresponding proteins. An evaluation of the comparative analyses of the
compositional, agronomic and phenotypic characteristics was undertaken, and the safety of the newly
expressed proteins and of the whole food/feed was evaluated with respect to potential toxicity,
allergenicity and nutritional wholesomeness. An evaluation of environmental impacts and the PMEM
plan was also undertaken. In accordance with the GMO Panel guidance documents applicable to this
application (EFSA, 2007), ‘Where all single events have been assessed, the risk assessment of stacked
events should focus mainly on issues related to (a) stability, (b) expression of the events and (c)
potential interactions between the events’.
The molecular data establish that the events stacked in soybean 305423 9 40-3-2 have retained
their integrity. Protein expression analyses showed that the levels of the newly expressed proteins in
the two-event stack and the parental lines are similar or present differences that are not unexpected.
There is no indication of an epistatic interaction between the events that may affect the levels of the
newly expressed proteins. No interaction at the functional level can be suspected from the known
biological functions of the newly expressed proteins.
The agronomic, phenotypic and compositional characteristics of soybean 305423 9 40-3-2 were
compared under ﬁeld conditions with those of the non-GM comparator (Jack) and three additional
comparators (a negative segregant of soybean 305423 9 40-3-2 and the single-event parental lines
soybean 305423 and 40-3-2), and tested for equivalence with a set of non-GM soybean reference
varieties. Differences were identiﬁed in soybean 305423 9 40-3-2 with respect to the comparators for
some agronomic endpoints, but these did not give rise to any food and feed or environmental safety
concern. Except for the altered fatty acid proﬁle (consistent with the intended trait), no food/feed
safety assessment was needed for the compositional differences identiﬁed between soybean
305423 9 40-3-2 and the comparators, or for any lack of equivalence in composition to the non-GM
soybean reference varieties. The comparison with the two parental lines did not reveal any potential
interaction that could be of concern for food and feed safety.
No concerns were identiﬁed regarding the potential toxicity and allergenicity of proteins GM-HRA
and CP4 EPSPS newly expressed in soybean 305423 9 40-3-2, and no evidence was found that the
genetic modiﬁcation might signiﬁcantly change its overall allergenicity. Nutritional assessment of oil and
other food products derived from soybean 305423 9 40-3-2 did not identify concerns for human
health and nutrition. Based on the assessment of the single event 305423, on compositional data
for soybean 305423 9 40-3-2 and on the results of a feeding study in chickens for fattening, there are
no concerns regarding the use of feedingstuffs derived from defatted toasted 305423 9 40-3-2
soybean meal.
Considering the intended, altered nutritional composition of soybean 305423 9 40-3-2, a proposal
for a post-market monitoring (PMM) plan needs to be provided by the applicant.
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Application EFSA-GMO-NL-2007-47 covers the import, processing, and food and feed uses of
soybean 305423 9 40-3-2, and excludes cultivation. Therefore, the ERA is concerned with the
accidental release into the environment of viable soybean 305423 9 40-3-2 seeds (i.e. during
transport and/or processing), and with the exposure to recombinant DNA of bacteria in the
gastrointestinal tract of animals fed GM material and bacteria present in environments exposed to their
faecal material (manure and faeces).
In the case of accidental release into the environment of viable seeds of soybean 305423 9 40-3-2,
there are no indications of an increased likelihood of establishment and spread of occasional feral
soybean 305423 9 40-3-2 plants, unless these plants are exposed to acetolactate-synthase (ALS)-
inhibiting or glyphosate-containing herbicides. Considering the scope of the application EFSA-GMO-NL-
2007-47, interactions with the biotic and abiotic environment are not considered to be relevant issues.
Risks associated with an unlikely, but theoretically possible, horizontal gene transfer from soybean
305423 9 40-3-2 to bacteria have not been identiﬁed.
Therefore, considering the introduced traits, the outcome of the comparative analysis, the routes of
exposure and the limited exposure levels, the GMO Panel concludes that soybean 305423 9 40-3-2
would not raise safety concerns in the event of accidental release of viable GM soybean seeds into the
environment.
The scope of the PMEM plan provided by the applicant and the reporting intervals are in line with
the intended uses of soybean 305423 9 40-3-2 and the GMO Panel guidelines on the PMEM of GM
plants.
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO- NL-
2007-47, additional information provided by the applicant, scientiﬁc comments submitted by the
Member States and relevant scientiﬁc publications. In conclusion, the GMO Panel is of the opinion that
the two-event stack soybean 305423 9 40-3-2, as described in this application, is as safe as the non-
GM comparator and the non-GM commercial soybean varieties with respect to potential effects on
human and animal health and the environment in the context of its scope.
As already stated in the frame of the analysis of event 305423, considering the modiﬁed nutritional
composition of soybean 305423 9 40-3-2, the GMO Panel considered a speciﬁc labelling proposal
provided by the applicant in accordance with Articles 13(2)(a) and 25(2)(c) of Regulation (EC)
No 1829/2003. The applicant proposed that food and feed products within the scope of the application
should be labelled as ‘genetically modiﬁed soybean with altered fatty acid proﬁle’. The GMO
Panel considers that this proposal is consistent with the compositional data provided for this soybean.
Scientiﬁc opinion on GM soybean 305423 3 40-3-2
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1. Introduction
1.1. Background
On 24 September 2007, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands application EFSA-GMO-NL-2007-47, for authorisation of genetically
modiﬁed (GM) soybean 305423 9 40-3-2 for food and feed uses, import and processing submitted
by Pioneer within the framework of Regulation (EC) No 1829/20031 on genetically modiﬁed food
and feed.
After receiving the application EFSA-GMO-NL-2007-47 and in accordance with Articles 5(2)(b) and
17(2)(b) of Regulation (EC) No 1829/2003, EFSA informed the Member States and the European
Commission, and made the summary of the application available to the public on the EFSA website.2
EFSA initiated a formal review of the application to check compliance with the requirements laid down
in Articles 5(3) and 17(3) of Regulation (EC) No 1829/2003. On 20 November 2007, EFSA received
additional information (requested on 12 November 2007). On 19 February 2008, EFSA declared the
application valid in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003.
EFSA made the valid application available to the Member States and the European Commission, and
consulted nominated risk assessment bodies of the Member States, including national Competent
Authorities within the meaning of Directive 2001/18/EC3 following the requirements of Articles 6(4)
and 18(4) of Regulation (EC) No 1829/2003 to request their scientiﬁc opinion. The Member States had
3 months after the opening of the Member State commenting period (until 19 May 2008) to make
their opinion known.
The Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority (GMO Panel)
carried out an evaluation of the scientiﬁc risk assessment of soybean 305423 9 40-3-2 for food and
feed uses, import and processing. The GMO Panel took into account the appropriate principles
described in its guidelines for the risk assessment of GM plants and derived food and feed (EFSA,
2006, 2007; EFSA GMO Panel, 2011a), the environmental risk assessment (ERA) of GM plants (EFSA
GMO Panel, 2010a) and on the post-market environmental monitoring (PMEM) of GM plants (EFSA
GMO Panel, 2011b). Additional information received after May 2011 was assessed in accordance with
2011 guidance (EFSA GMO Panel, 2011a). Furthermore, the GMO Panel also took into consideration
the scientiﬁc comments of the Member States, the additional information provided by the applicant
and relevant scientiﬁc publications.
On 8 December 2009, 13 February 2014, 1 April 2014, 22 May 2014, 4 July 2014, 25 July 2014,
4 September 2014, 10 November 2014, 10 February 2015, 21 April 2015, 5 May 2015, 10 September
2015, 8 December 2015 and 21 April 2016, the GMO Panel requested additional information from the
applicant. The applicant provided the requested information on 27 January 2010, 26 February 2014,
22 April 2014, 20 June 2014, 3 July 2014, 24 July 2014, 9 September 2014, 6 October 2014,
1 December 2014, 16 April 2015, 13 May 2015, 29 June 2015, 25 September 2015, 1 February 2016
and on 19 May 2016. The applicant also provided spontaneously additional information on 5 December
2013, 30 July 2015 and on 9 November 2015. The clock of the application was stopped on
29 February 2008 and maintained stopped from 15 December 2010 to 10 December 2013 due to the
pending assessment of the single-event soybean 305423 (application reference EFSA-GMO-NL-
2007-45). The applicant provided clariﬁcations on the Labelling proposal of the application on
3 September 2015.
In giving its scientiﬁc opinion to the European Commission, the Member States and the applicant,
and in accordance with Articles 6(1) and 18(1) of Regulation (EC) No 1829/2003, EFSA has
endeavoured to respect a time limit of 6 months from the acknowledgement of the valid application. As
additional information was requested by the GMO Panel, the time limit of 6 months was extended
accordingly, in line with Articles 6(1), 6(2), 18(1) and 18(2) of Regulation (EC) No 1829/2003.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2007-175
3 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
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1.2. Terms of Reference as provided by the requestor
The GMO Panel was requested to carry out a scientiﬁc assessment of soybean 305423 9 40-3-2 for
food and feed uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation (EC)
No 1829/2003.
Where applicable, any conditions or restrictions which should be imposed on the placing on the
market and/or speciﬁc conditions or restrictions for use and handling, including post-market monitoring
(PMM) requirements based on the outcome of the risk assessment and, in the case of GMOs or
food/feed containing or consisting of GMOs, conditions for the protection of particular ecosystems/
environment and/or geographical areas should be indicated in accordance with Articles 6(5)(e) and
18(5)(e) of Regulation (EC) No 1829/2003.
The GMO Panel was not requested to give an opinion on information required under Annex II to
the Cartagena Protocol. The GMO Panel did consider if there is a need for speciﬁc labelling in
accordance with Articles 13(2) (a) and 25(2)(c) of Regulation (EC) No 1829/2003. However, it did not
consider proposals for methods of detection (including sampling and the identiﬁcation of the speciﬁc
transformation event in the food/feed and/or food/feed produced from it), which are matters related
to risk management.
2. Data and methodologies
2.1. Data
In delivering its scientiﬁc opinion, the GMO Panel took into account application EFSA-GMO-NL-2007-
47, additional information provided by the applicant, scientiﬁc comments submitted by the Member
States and relevant scientiﬁc publications.
2.2. Methodologies
The GMO Panel carried out a scientiﬁc risk assessment of soybean 305423 9 40-3-2 for food and
feed uses, import and processing in accordance with Articles 6(6) and 18(6) of Regulation (EC)
No 1829/2003. The GMO Panel took into account the appropriate principles described in its guidelines
for the risk assessment of GM plants and derived food and feed (EFSA, 2006, 2007; EFSA GMO Panel,
2011a), for the ERA of GM plants (EFSA GMO Panel, 2010a) and for the PMEM of GM plants (EFSA
GMO Panel, 2011b).
The comments raised by the Member States are addressed in Annex G of EFSA’s overall opinion4
and were taken into consideration during the scientiﬁc risk assessment.
3. Assessment
3.1. Introduction
Application EFSA-GMO-NL-2007-47 covers a two-event stack soybean 305423 9 40-3-2 produced
by conventional crossing. The scope of this application is for food and feed uses, import and
processing, but excludes cultivation in the European Union (EU).
Soybean 305423 9 40-3-2 was developed to confer tolerance to acetolactate-synthase (ALS)-
inhibiting herbicides and glyphosate (N-(phosphonomethyl)glycine)-based herbicides and to have an
altered fatty acid proﬁle (increased oleic acid content). Tolerance to ALS-inhibiting herbicides is
conferred by the expression of the Glycine max herbicide-resistant ALS (GM-HRA) protein; tolerance to
glyphosate is achieved by expression of the CP4 5-enolpyruvylshikimate-3-phosphate synthase (CP4
EPSPS). The high-oleic acid phenotype is achieved by introducing a fragment of the soybean fad2-1
gene, under the control of a promoter driving expression mainly in the seeds. The genetic modiﬁcation
results in the suppression of the expression of the endogenous omega-6 desaturase via RNA
interference (RNAi).
The two single soybean events 305423 and 40-3-2 have been previously assessed (Table 1) and no
concerns for human and animal health or environmental safety were identiﬁed.
4 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2016-00198
Scientiﬁc opinion on GM soybean 305423 3 40-3-2
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2016;14(8):4566
The EFSA guidance applicable to this application establishes that ‘Where all single events have been
assessed, the risk assessment of stacked events should focus mainly on issues related to (a) stability,
(b) expression of the events and (c) potential interactions between the events’ (EFSA, 2007).
Additional information received after May 2011 was assessed in accordance with 2011 guidance (EFSA
GMO Panel, 2011a).
3.2. Updated information on single events
Since the publication of the scientiﬁc opinions on the single soybean events by the GMO
Panel (EFSA GMO Panel, 2010b, 2012a, 2013), no safety issue pertaining to the two single events has
been reported by the applicant.
Updated bioinformatic analyses on the junction regions for events 305423 and 40-3-2 conﬁrmed
that no known endogenous genes were disrupted by any of the inserts.5 Updated bioinformatic
analyses of the amino acid sequence of the newly expressed proteins revealed no signiﬁcant
similarities to known toxins.5 An updated search for similarity of the newly expressed proteins to
allergens was performed applying the criterion of > 35% identity in an 80 amino acid sliding window.5
This analysis did not reveal any new information regarding the similarity of GM-HRA and CP4 EPSPS
proteins to known allergens. In addition, updated bioinformatic analyses of the newly created open
reading frames (ORFs) within the inserts and at their junctions indicate that the expression of an ORF
showing signiﬁcant similarities to toxins or allergens is highly unlikely.5
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single soybean events remain valid.
3.3. Molecular characterisation
Possible interactions affecting the integrity of the single events, protein expression levels or the
biological function conferred by the individual inserts are considered.
3.3.1. Genetic elements and biological functions of the inserts
The two single events 305423 and 40-3-2 are combined by conventional crossing to produce the
two-event stack soybean 305423 9 40-3-2. The structures of the inserts introduced into the two-event
stack soybean are described in detail in the respective EFSA scientiﬁc opinions (Table 1) and no new
genetic modiﬁcations were involved. Genetic elements in the expression cassettes of the single events
are summarised in Table 2.
Table 1: Single soybean events already assessed by the EFSA Panel on Genetically Modiﬁed
Organisms (GMO Panel)
Event Application or mandate EFSA Scientiﬁc Opinion
305423 EFSA-GMO-NL-2007-45 EFSA GMO Panel (2013)
40-3-2 EFSA-GMO-NL-2005-24
EFSA-GMO-RX-40-3-2
EFSA GMO Panel (2012a)
EFSA GMO Panel (2010b)
Table 2: Genetic elements in the expression cassettes of the events stacked in soybean
305423 9 40-3-2
Event Promoter 50 UTR Transit peptide Coding region Terminator
305423 KTi3 (Glycine max) – – fad2-1 (non-coding
fragment) (G. max)
KTi3 (G. max)
S-adenosyl-L-
methionine
synthetase (SAMS)
(G. max)
50 UTR and
intron from
SAMS (G. max)
– gm-hra (G. max) als (G. max)
5 Additional information: 16/4/2015.
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Intended effects of the inserts in soybean 305423 9 40-3-2 are summarised in Table 3.
Based on the known biological function of the newly expressed proteins (Table 3), no foreseen
interactions at the biological level are expected.
3.3.2. Integrity of the events in soybean 305423 3 40-3-2
The genetic stability of the inserted DNA over multiple generations in the single soybean events
305423 and 40-3-2 was demonstrated previously (EFSA GMO Panel, 2010b, 2012a, 2013). Integrity of
these events was demonstrated by Southern analyses.6,7 Additional real-time polymerase chain
reaction data was provided demonstrating the presence of all the inserts deriving from soybean
305423 in the two-event stack.7
3.3.3. Information on the expression of the inserts8
Plants were grown in 2005 (six locations, three replicate plots) and in 2011 (10 locations, four
replicate plots) under ﬁeld conditions in the USA and in Canada.9,10 The levels of GM-HRA and CP4
EPSPS proteins in the two-event stack soybean and the two single events were quantiﬁed by enzyme-
linked immunosorbent assay (ELISA). Protein levels were determined in leaves (V2, V5, R1 (only in
2011) and R3 stages), forage (R3 stage), roots (R3 stage) and in seeds (R8 stage). Data on seeds are
Event Promoter 50 UTR Transit peptide Coding region Terminator
40-3-2 35S (CaMV) – CTP4
(Petunia hybrida)
CP4 epsps
(Agrobacterium
tumefaciens)
nos
(A. tumefaciens)
CAMV: cauliﬂower mosaic virus; UTR: untranslated region; CTP4: chloroplast transit peptide 4; fad: fatty acid desaturase;
gm-hra: Glycine max herbicide-resistant ALS; epsps: 5-enolpyruvylshikimate-3-phosphate synthase; KTi3: Kunitz trypsin inhibitor
gene 3; als: acetolactate synthase; nos: nopaline synthase.
–: no element was speciﬁcally introduced to optimise expression
Table 3: Characteristics and intended effects of the events stacked in soybean 305423 9 40-3-2
Event Protein Donor organism and biological function Intended effects in GM plant
305423 FAD2-1(a)
GM-HRA
Donor organism: Glycine max. The full-length
FAD2-1 protein is an omega-6 desaturase in
soybean. Its expression is seed-speciﬁc and
the enzyme is responsible for the synthesis
of the polyunsaturated fatty acids found in
soybean oil (Heppard et al., 1996).
Donor organism: G. max Acetohydroxyacid
synthase (AHAS or ALS) is a key enzyme that
catalyses the ﬁrst common step in the
biosynthesis of the essential branched-chain
amino acids isoleucine, leucine and valine
(Coruzzi and Last, 2000; Duggleby and Pang,
2000; LaRossa and Falco, 1984; LaRossa and
Schloss, 1984)
The inserted fragment of fad2-1 does
not code for a functional protein,
rather suppresses the expression
of the endogenous omega-6
desaturase by RNAi, resulting in an
increased oleic acid phenotype
GM-HRA is a modiﬁed version of the
endogenous ALS enzyme that
confers tolerance to ALS-inhibiting
herbicides (Hartnett et al., 1990)
40-3-2 CP4 EPSPS Donor organism: Agrobacterium sp.
5-enopyruvyl-shikimate-3-phospate synthase
(EPSPS) synthase is an enzyme involved in the
shikimic acid pathway for aromatic amino acid
biosynthesis in plants and microorganisms
(Herrmann, 1995)
The bacterial CP4 EPSPS confers
tolerance to glyphosate-containing
herbicides, as it has a greatly
reduced afﬁnity towards glyphosate
as compared to the plant
endogenous enzyme
FAD: Fatty Acid Desaturase; GM-HRA: Glycine max herbicide-resistant ALS.
(a): Gene fragment of the endogenous omega-6 desaturase.
6 Dossier: Part I – Section D2.
7 Additional information: 25/9/2015.
8 Dossier: Part I – Section D3.
9 Dossier: Part I – Annex 4.
10 Additional information: 5/12/2013 – Annex 3.
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reported in Table 4. GM-HRA and CP4 EPSPS protein levels in the two-event stack soybean were
similar to the corresponding levels in the single soybean events and showed no major changes that
could be the results of an interaction between the events.
In addition to protein expression analyses, the presence of the high-oleic acid phenotype and
herbicide tolerance in soybean 305423 9 40-3-2 was also demonstrated by Northern analysis of the
fad2-1 gene transcript, gas chromatography and lateral-ﬂow test for the CP4 EPSPS protein.11
3.3.4. Conclusion
The molecular data establish that the events stacked in soybean 305423 9 40-3-2 have retained their
integrity. Protein expression analyses showed that the levels of the newly expressed proteins are similar
to the corresponding levels in the single soybean events. Therefore, there is no indication of interaction
that may affect the integrity of the events and the levels of the newly expressed proteins in this stack.
Based on the known biological function of the newly expressed proteins, no foreseen interactions at
the biological level are expected.
3.4. Comparative analyses
3.4.1. Choice of comparator and production of material for the comparative
assessment12
In the context of this application, the applicant submitted data from two different ﬁeld trials studies
(Table 5).
Table 4: Means, standard deviations and ranges (n = 18 and n = 40 for 2005 and 2011 values,
respectively) of protein levels in seeds (lg/g dry weight) from soybean 305423 9 40-3-2
and from single soybean events 305423 and 40-3-2
305423 3 40-3-2 305423 40-3-2
Tissue/protein
Untreated(a) Treated(b) Untreated Treated Untreated Treated
Grain (2005)
GM-HRA 3.1(c)  0.85(d)
(1.9–4.6)(e)
2.7  1.0
(1.8–5.9)
2.5  1.1
(0–4.9)
2.5  0.54
(1.7–3.5)
– –
CP4 EPSPS 410  70
(320–520)
400  70
(310–550)
– – 320  50
(220–430)
340  70
(230–500)
Grain (2011)
GM-HRA 3.1  0.67
(1.2–4.8)
2.9  0.51
(2.1–4.0)
4.6  0.78
(3.1–6.6)
4.4  1.3
(< 0.54–7.2)
– –
CP4 EPSPS 770  280
(340–1,400)
770  310
(200–1,800)
– – 500  190
(280–1,300)
460  140
(280–840)
–: not assayed.
(a): Untreated: Plants were treated with conventional herbicides (quizalofop p-ethyl- and fomesafen-containing herbicides).
(b): Treated: Plants were treated with intended herbicides (ALS-inhibiting (chlorimuron and thifensulfuron) and/or glyphosate-
containing herbicides).
(c): Mean.
(d): Standard deviation.
(e): Range.
11 Dossier: Part I – Annex 2, 3 and 5.
12 Dossier: Part I – Annex 4; additional information: 5/12/2013, 22/4/2014, 20/6/2014, 25/7/2014, 6/10/2014, 1/12/2014, 29/6/
2015, 9/11/2015, 1/2/2016 and 19/5/2016.
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In the 2005 ﬁeld trials,9 soybean 305423 9 40-3-2 was compared to a negative segregant line
(generation BC1F5) not containing the events 40-3-2 and 305423. The GMO Panel is of the opinion that
potential unintended effects linked to the genetic modiﬁcation process in the GM plant cannot be
identiﬁed using a negative segregant as the sole comparator (EFSA GMO Panel, 2011a,c). Therefore,
the GMO Panel considers that the ﬁeld trials performed in 2005 are not appropriate.
The 2011 ﬁeld trials were performed at ten sites in the major soybean growing regions of North
America.13 The materials were treated either with conventional herbicides14 (CHT) or with the intended
herbicides15 (IHT). At each site, the following materials were grown: soybean 305423 9 40-3-2 (CHT),
soybean 305423 9 40-3-2 (IHT), the non-GM soybean variety Jack (CHT), a negative segregant of
305423 9 40-3-2 (CHT), the parental line single-event soybean 305423 (CHT and IHT), the parental
line single-event soybean 40-3-2 (CHT and IHT) and three commercial non-GM soybean reference
varieties (CHT; out of ten varieties in total16). A randomised complete block design with four replicates
of each material was used at each site. The material harvested in these ﬁeld trials was used for
compositional analyses of forage and seeds.
In the ﬁrst analysis of the 2011 ﬁeld trials,17 soybean 305423 9 40-3-2 was compared to the non-GM
soybean variety Jack (Table 5). On the basis of the breeding diagram and the estimated genetic
similarity with the stack, the GMO Panel concluded that Jack is a suboptimal comparator, and that it
cannot be used as the sole comparator for the agronomic, phenotypic and compositional
characterisation of soybean 305423 9 40-3-2.
In order to address the limitations related to the choice of Jack, the GMO Panel asked the applicant
to provide the complete data set from the 2011 ﬁeld trials, which included materials that could be
used as additional comparators. These additional comparators were: the selected negative segregant
of soybean 305423 9 40-3-2 (generation BC1F7); the parental line single-event soybean 305423
(CHT); and the parental line single-event soybean 40-3-2 (CHT). The use of additional comparators,
including parental lines and negative segregants, is foreseen if deemed useful to support the risk
assessment (EFSA GMO Panel 2011a,c). The GMO Panel based its assessment on the analysis carried
out on the complete data set.18
The statistical analysis of agronomic, phenotypic and compositional data from the 2011 ﬁeld trials
was carried out in line with the applicable EFSA Guidance (EFSA GMO Panel, 2011a). This includes the
application of a test of difference and a test of equivalence to each endpoint.
• The test of difference determines whether or not the GM plant is different from its comparator.
In the analysis of the 2011 ﬁeld trials, the test of difference was performed between soybean
305423 9 40-3-2 (CHT and IHT) and each of the four comparators:
– Jack;
– the negative segregant;
– soybean 305423 (CHT);
– soybean 40-3-2 (CHT).
Table 5: Overview of the ﬁeld trial studies for the comparative assessment of agronomic and
phenotypic characteristics and composition of soybean 305423 9 40-3-2
Study details
Comparators
Non-GM commercial
reference varietiesNon-GM
comparator
Negative
segregant
Parental lines
USA and Canada, 2005, six locations – BC1F5 – –
USA and Canada, 2011, 10 locations Jack BC1F7 40-3-2 and 305423 Ten varieties
GM: Genetically modiﬁed.
–: The material was not grown in the ﬁeld trials.
13 Nine sites were in the USA: Iowa (two sites), Illinois (two sites), Kansas, Minnesota, Nevada, Pennsylvania and Wisconsin. One
site was in Canada (Ontario).
14 The conventional herbicides were a tank mix of herbicides with the active ingredients quizalofop p-ethyl and fomesafen.
15 The intended herbicides were: chlorimuron, thifensulfuron, and glyphosate for soybean 305423 9 40-3-2; chlorimuron and
thifensulfuron for soybean 305423; glyphosate for soybean 40-3-2.
16 The commercial non-GM soybean reference materials were the Pioneer brand lines 92M10, 92M22, 92M72, 92Y21, 93B82,
93M14, 93M52, 93M62, 93Y21 and 93Y41.
17 Additional information: 5/12/2013.
18 Additional information: 1/2/2016 and 19/5/2016.
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• The test of equivalence determines whether or not the GM plant (here, soybean
305423 9 40-3-2 CHT and IHT) falls within the range of natural variation estimated from the
non-GM soybean reference varieties. The results of the equivalence test are categorised into
four possible outcomes (I–IV, from equivalence to non-equivalence).19
In the rest of this Section, the herbicide treatment (CHT/IHT) will be explicitly indicated only for
soybean 305423 9 40-3-2; for all the other materials that will be discussed, it is speciﬁed here that
the herbicide treatment is CHT.
Regarding the test of difference, the GMO Panel assessed the results of the four sets of
comparisons as follows:
• The GMO Panel considered that the use of a negative segregant as additional comparator is a
suitable way to address the limitations related to the choice of Jack. Therefore, the results of
the comparison of soybean 305423 9 40-3-2 with the negative segregant were assessed
together with the results obtained with Jack. The comparison with the negative segregant may
in general identify additional differences (not identiﬁed in the comparison with Jack) to be
included in the risk assessment. The GMO Panel took the conservative approach of considering
all the differences identiﬁed in the two comparisons, with no priority given to either
comparator, as indicators of effects linked to the genetic modiﬁcation. Every difference in the
two sets of comparisons was therefore independently assessed.
• The results of the comparison of soybean 305423 9 40-3-2 with the two parental lines (single-
events soybean 305423 and soybean 40-3-2) were used for the identiﬁcation of differences
that may be linked to interaction between the two single events. In addition, the comparison
of soybean 305423 9 40-3-2 with the parental line soybean 305423 was used to conﬁrm the
effects of the genetic modiﬁcation on the fatty acid proﬁle.
3.4.2. Agronomic and phenotypic analysis18
Ten phenotypic and agronomic endpoints were measured at the 10 ﬁeld trial sites in North America
in 2011 (Table 5): early stand count, days to maturity, plant height, ﬁnal stand count, pod shattering,
yield, seedling vigour, lodging, disease incidence and insect damage. Nine of them were analysed with
difference and equivalence testing (the remaining endpoint, pod shattering, did not fulﬁl the
requirements of the statistical tests).
The results of the tests of difference were as follows:
• In the comparison with Jack, signiﬁcant differences for soybean 305423 9 40-3-2 (both CHT
and IHT) were identiﬁed for four endpoints: early population, plant height, lodging and ﬁnal
population; signiﬁcant differences between Jack and soybean 305423 9 40-3-2 (CHT) were
identiﬁed for two endpoints: days to maturity and yield.
• In the comparison with the negative segregant, signiﬁcant differences for soybean
305423 9 40-3-2 (both CHT and IHT) were identiﬁed for four endpoints: early population,
plant height, ﬁnal population and yield; signiﬁcant differences between the negative segregant
and soybean 305423 9 40-3-2 (CHT) were identiﬁed for two endpoints: insect damage and
lodging.
• In the comparison with soybean 305423, signiﬁcant differences for soybean 305423 9 40-3-2
(both CHT and IHT) were identiﬁed for six endpoints: early population, insect damage, days to
maturity, lodging, ﬁnal population and plant height; a signiﬁcant difference between soybean
305423 and soybean 305423 9 40-3-2 (IHT) was identiﬁed for the endpoint yield.
• In the comparison with soybean 40-3-2, signiﬁcant differences for soybean 305423 9 40-3-2
(both CHT and IHT) were identiﬁed for six endpoints: early population, disease incidence, days
to maturity, ﬁnal population, lodging and plant height.
The test of equivalence19 showed that all the endpoints analysed in 305423 9 40-3-2 soybean (both
CHT and IHT) were equivalent to the non-GM soybean reference varieties (equivalence category I).
The GMO Panel concludes that taking all data together, the phenotypic and agronomic
characteristics of soybean 305423 9 40-3-2 are comparable to the commercial non-GM soybean
varieties, except for the introduced traits (tolerance to herbicides). The differences in agronomic and
19 In detail, the four outcomes are: category I (indicating full equivalence); category II (equivalence is more likely than non-
equivalence); category III (non-equivalence is more likely than equivalence); and category IV (indicating non-equivalence)
(EFSA GMO Panel 2011a).
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phenotypic characteristics identiﬁed between soybean 305423 9 40-3-2 and the comparators are
further discussed for their potential environmental impact in Section 3.6.
3.4.3. Compositional analysis18
The seeds and forage of the soybean materials harvested from the ﬁeld trials in North America in
2011 (Table 5) were analysed for 101 constituents (eight in forage and 93 in seeds), including the key
constituents recommended for soybean by OECD (2001). Eighteen seed constituents20 with 50% or
more sample values below the lower limit of quantiﬁcation were excluded from the comparative
analysis, which therefore included 83 endpoints (eight in forage and 75 in seeds, of which 17 fatty
acids).
The GMO Panel has already assessed data on the composition of soybean 305423 and soybean 40-
3-2 (EFSA GMO Panel, 2010b, 2012a, 2013). The composition of soybean 40-3-2 was found equivalent
to that of its conventional counterparts (A5403 and Dekabig) and commercial soybean varieties (EFSA
GMO Panel, 2010b, 2012a). The composition of soybean 305423 was found different from the
conventional counterpart (Jack) and commercial soybean varieties in having an altered fatty acid
proﬁle (EFSA GMO Panel, 2013).
In the following, a detailed discussion is provided of results for the fatty acid proﬁle and, separately,
for the other endpoints.
3.4.3.1. Results for the fatty acid proﬁle
Statistical results (outcomes and estimates) for the 17 fatty acids21 are reported in Table 6.
The outcomes of the test of difference for were the following:
• In the comparison with Jack, all the 17 fatty acids analysed were found signiﬁcantly different
from both treatments of soybean 305423 9 40-3-2 (CHT/IHT), with the exception of
palmitoleic acid (C16:1).
• In the comparison with the negative segregant, all the 17 fatty acids analysed were found
signiﬁcantly different for soybean 305423 9 40-3-2 (both CHT and IHT).
• In the comparison with soybean 305423, 10 signiﬁcant differences were identiﬁed for
305423 9 40-3-2 (CHT) and 11 signiﬁcant differences for 305423 9 40-3-2 (IHT).
• In the comparison with soybean 40-3-2, all the 17 fatty acids analysed were found signiﬁcantly
different from soybean 305423 9 40-3-2 (both CHT and IHT).
The outcomes of test of equivalence19 for the two herbicide treatments of soybean 305423 9 40-3-2
(CHT and IHT) were identical for each of the 17 endpoints. The level of three fatty acids in soybean
305423 9 40-3-2 fell under equivalence category I: palmitoleic acid (C16:1), stearic acid (C18:0) and
(9,15) isomer of linoleic acid (C18:2). The level of the remaining 14 fatty acids in soybean
305423 9 40-3-2 fell under equivalence category III or IV.
20 The endpoints excluded from the statistical analysis were sodium, genistein, glycitein, coumestrol and 14 fatty acids: caprylic
(C8:0), capric (C10:0), lauric (C12:0), myristoleic (C14:1), pentadecanoic (C15:0), pentadecenoic (C15:1), heptadecadienoic
(C17:2), c-linolenic (C18:3), nonadecanoic (C19:0), isomer 1 of nonadecenoic (C19:1), eicosadienoic (C20:2), eicosatrienoic
(C20:3), arachidonic (C20:4) and erucic (C22:1).
21 The fatty acids analysed were: myristic (C14:0), palmitic (C16:0), palmitoleic (C16:1), heptadecanoic (C17:0), heptadecenoic
(C17:1), stearic (C18:0), oleic (C18:1), linoleic (C18:2), (9,15) isomer of linoleic acid (C18:2), a-linolenic (C18:3), isomer 2 of
nonadecenoic acid (C19:1), arachidic (C20:0), eicosenoic (C20:1), heneicosanoic (C21:0), behenic (C22:0), tricosanoic (C23:0)
and lignoceric (C24:0).
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Table 6: Statistical results for the 17 fatty acids: means (for the two-event stack soybean
305423 9 40-3-2 and the four comparators) and equivalence limits (from the non-GM
reference varieties) estimated from the 2011 ﬁeld trials (Table 5)
Fatty acids
(% total FA)
Soybean
305423 3 40-3-2
Comparator
Equivalence
limits from
non-GM
reference
varieties
CHT(a) IHT(b) Jack
Negative
segregant
Soybean
305423
Soybean
40-3-2
Saturated fatty acids
Myristic acid
(C14:0)
0.0472 0.0484 0.0675 0.0686 0.0482(c,d) 0.0727 (0.0595, 0.0843)
Palmitic acid
(C16:0)
6.17 6.17 10.1 10.2 6.48 10.2 (9.81, 11.3)
Heptadecanoic
acid (C17:0)
0.781 0.783 0.116 0.117 0.772(c) 0.114 (0.0996, 0.121)
Stearic acid
(18:0)
4.35 4.40 4.17 4.64 4.17 5.25 (3.47, 5.07)
Arachidic acid
(C20:0)
0.423 0.428 0.322 0.361 0.421(c) 0.410 (0.275, 0.399)
Heneicosanoic
acid (C21:0)
0.0566 0.0639 0.0191 0.0205 0.0552(c,d) 0.0385 (0.0137, 0.0322)
Behenic acid
(C22:0)
0.402 0.406 0.328 0.347 0.433 0.368 (0.288, 0.373)
Tricosanoic acid
(C23:0)
0.0684 0.0688 0.0531 0.0598 0.0638 0.0605 (0.0417, 0.0678)
Lignoceric acid
(C24:0)
0.175 0.180 0.146 0.150 0.202 0.149 (0.108, 0.174)
Monounsaturated fatty acids
Palmitoleic acid
(C16:1)
0.112 0.116 0.112(c) 0.106 0.122 0.122 (0.102, 0.144)
Heptadecenoic
acid (C17:1)
1.23 1.23 0.0594 0.0542 1.24(c,d) 0.0591 (0.0534, 0.071)
Oleic acid
(C18:1)
74.4 74.8 19.3 19.4 74.5(c,d) 21.3 (17, 22)
Nonadecenoic
acid (C19:1)
isomer 2
0.303 0.304 0.0497 0.0511 0.294(c,d) 0.0477 (0.0395, 0.0693)
Eicosenoic acid
(C20:1)
0.362 0.361 0.174 0.183 0.353 0.188 (0.164, 0.206)
n-3 polyunsaturated fatty acids
Isomer (9,15) of
linoleic acid
(C18:2)
0.721 0.752 0.642 0.62 0.766(d) 0.658 (0.499, 0.915)
a-Linolenic acid
(C18:3)
5.26 5.18 8.17 8.79 4.94 8.22 (6.97, 9.58)
n-6 polyunsaturated fatty acids
Linoleic acid
(C18:2)
4.35 4.17 50.0 48.9 4.83 47.0 (36.8, 77.5)
The outcomes of the difference test are shown in the entries for the comparators: entries that are not signiﬁcantly different from
the stack (CHT, IHT or both) are marked with upper indices(c),(d),(c,d); for entries with no indices, the stack (CHT/IHT) is
signiﬁcantly different from the comparator. The outcomes of the equivalence test are shown in the entries for the stack, and are
differentiated by greyscale backgrounds: white (equivalence category I), light grey (equivalence category III) and dark grey
(equivalence category IV).
(a): Treated with conventional herbicides (quizalofop p-ethyl and fomesafen).
(b): Treated with the intended herbicides (chlorimuron, thifensulfuron and glyphosate).
(c): No signiﬁcant difference identiﬁed between 305423 9 40-3-2 (CHT) and the comparator.
(d): No signiﬁcant difference identiﬁed between 305423 9 40-3-2 (IHT) and the comparator.
(c,d): No signiﬁcant differences identiﬁed between 305423 9 40-3-2 (both CHT and IHT) and the comparator.
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In interpreting the results in Table 6, the two comparisons with Jack and the negative segregant
are considered ﬁrst, followed by the comparisons with soybean 305423 and soybean 40-3-2.
Several of the signiﬁcant differences identiﬁed in the comparison of soybean 305423 9 40-3-2 with
Jack and with the negative segregant are consistent with the intended effect of the genetic
modiﬁcation characterising event 305423 (EFSA GMO Panel, 2013): an increase in oleic acid (C18:1) at
the expense of the polyunsaturated fatty acids linoleic (18:2) and a-linolenic (18:3). Further changes
associated to the intended effect are the increase in eicosenoic acid (20:1) and the decrease in
myristic acid (14:0) and palmitic acid (16:0). All these endpoints fell under equivalence category IV.
Another set of signiﬁcant differences corresponds to an expected unintended effect associated to
soybean event 305423 (EFSA GMO Panel, 2013): an increase in the levels of odd-chain fatty acids
(e.g. heptadecanoic acid (C17:0) and heptadecenoic acid (C17:1)); all these endpoints fell under
equivalence categories III or IV. An explanation considered plausible by the GMO Panel is that the
GM-HRA enzyme may have a decreased afﬁnity for 2-ketobutyrate. This may lead to an increased pool
of 2-ketobutyrate available for odd chain fatty acid biosynthesis, hence to increased levels of odd chain
fatty acids in soybean 305423 9 40-3-2 (EFSA GMO Panel, 2013).
The results of the comparison of soybean 305423 9 40-3-2 with soybean 305423 show that the
intended and expected unintended effects linked to event 305423 occur consistently in the single
event and in the two-event stack. Of the endpoints associated to the two effects, several were
found not signiﬁcantly different between soybean 305423 9 40-3-2 (CHT/IHT) and soybean 305423
(e.g. oleic acid (18:1), heptadecenoic acid (C17:1)). Several other endpoints were signiﬁcantly
different (e.g. linoleic acid (18:2)); however, in all those cases, the levels in soybean 305423 9 40-3-
2 were much closer to soybean 305423 than to Jack or the negative segregant. Overall, this
conﬁrms that the pattern of the fatty acid proﬁle is maintained in the two-event stack.
The results of the comparison of soybean 305423 9 40-3-2 with the two single parental lines did
not provide evidence of an impact of the combination of the two events 305423 and 40-3-2 on the
overall fatty acid proﬁle of 305423 9 40-3-2.
The changed fatty acid proﬁle of 305423 9 40-3-2 is assessed for possible nutritional and safety
implications in Section 3.5.5.
3.4.3.2. Results for the other compounds
The outcome of the test of difference for compounds other than fatty acids (eight in forage and 58
in seed22) was the following:
• In the comparison with Jack, signiﬁcant differences with soybean 305423 9 40-3-2 (CHT)
were identiﬁed for 42 compounds (40 in seed and two in forage); signiﬁcant differences
with soybean 305423 9 40-3-2 (IHT) were identiﬁed for 45 compounds (41 in seed and four
in forage).23
• In the comparison with the negative segregant, signiﬁcant differences with soybean
305423 9 40-3-2 (CHT) were identiﬁed for 42 compounds (38 in seed and four in forage);
22 Endpoints in forage: ash, carbohydrates, moisture, crude protein, crude fat, crude ﬁbre, acid detergent ﬁbre (ADF), neutral
detergent ﬁbre (NDF). Endpoints in seed: proximates and ﬁbres (ash, carbohydrates, moisture, crude protein, crude fat, crude
ﬁbre, ADF, NDF), amino acids (alanine, arginine, aspartic acid, cystine, glutamic acid, glycine, histidine, isoleucine, leucine,
lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine), minerals (calcium, copper, iron,
magnesium, manganese, phosphorus, potassium, sodium, zinc), vitamins (vitamin B1 (thiamine), vitamin B2 (riboﬂavin),
vitamin B3 (niacin), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B9 (folic acid), a-tocopherol, b-tocopherol,
c-tocopherol, d-tocopherol, total tocopherols), isoﬂavones (daidzein, daidzin, genistein, genistin, glycitein, glycitin, total
daidzein, total genistein, total glycitein), oligosaccharides (rafﬁnose, stachyose, sucrose), secondary metabolites and
antinutrients (coumestrol, lectins, phytic acid, trypsin inhibitor).
23 Signiﬁcantly different forage endpoints identiﬁed in the comparison between soybean 305423 9 40-3-2 and Jack: ADF (for
soybean 305423 9 40-3-2 CHT and IHT), ash (CHT, IHT), crude ﬁbre (IHT) and NDF (IHT). Signiﬁcantly different seed
endpoints: ADF (IHT), carbohydrates (IHT), crude fat (CHT, IHT), crude ﬁbre (CHT, IHT), alanine (CHT, IHT), aspartic acid
(CHT, IHT), cystine (IHT), glutamic acid (IHT), glycine (CHT, IHT), isoleucine (CHT, IHT), leucine (CHT, IHT), methionine
(IHT), phenylalanine (CHT, IHT), proline (CHT), serine (CHT), threonine (CHT, IHT), tryptophan (CHT, IHT), tyrosine (CHT,
IHT), valine (CHT, IHT), calcium (CHT, IHT), copper (IHT), iron (CHT, IHT), manganese (CHT, IHT), potassium (CHT), zinc
(CHT, IHT), a-tocopherol (CHT, IHT), d-tocopherol (CHT, IHT), c-tocopherol (CHT, IHT), total tocopherols (CHT, IHT), vitamin
B1 (thiamine) (CHT, IHT), vitamin B2 (riboﬂavin) (CHT, IHT), vitamin B5 (pantothenic acid) (CHT, IHT), vitamin B6
(pyridoxine) (CHT, IHT), vitamin B9 (folic acid) (CHT, IHT), daidzein (CHT, IHT), daidzin (CHT, IHT), genistin (CHT), glycitin
(CHT, IHT), total daidzein (CHT, IHT), total genistein (CHT), total glycitein (CHT, IHT), rafﬁnose (CHT, IHT), stachyose (CHT,
IHT), sucrose (CHT, IHT), lectins (CHT, IHT), trypsin inhibitor (CHT, IHT).
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signiﬁcant differences with soybean 305423 9 40-3-2 (IHT) were identiﬁed for 45
compounds (39 in seed and six in forage).24
• In the comparison with the parental line soybean 305423, signiﬁcant differences with soybean
305423 9 40-3-2 (CHT) were identiﬁed for 40 compounds (34 in seed and six in forage);
signiﬁcant differences with soybean 305423 9 40-3-2 (IHT) were identiﬁed for 38 compounds
(35 in seed and three in forage).25
• In the comparison with the parental line soybean 40-3-2, signiﬁcant differences with soybean
305423 9 40-3-2 (CHT) were identiﬁed for 47 compounds (42 in seed and ﬁve in forage);
signiﬁcant differences with soybean 305423 9 40-3-2 (IHT) were identiﬁed for 33 compounds
(31 in seed and two in forage).26
All the signiﬁcant differences from the four comparisons were assessed; no issues were identiﬁed.
The comparison of soybean 305423 9 40-3-2 with the two single parental lines, soybean 305423 and
soybean 40-3-2, did not provide indication of interactions that would be of concern for food and feed
safety or nutrition.
The test of equivalence19 showed that for soybean 305423 9 40-3-2 (both CHT and IHT) 51 seed
endpoints and seven forage endpoints fell under equivalence category I or II: these endpoints were
not considered further. Six seed endpoints, which fell under equivalence category III or IV, and two
endpoints for which the equivalence test could not be performed (because of the small variation
among the non-GM reference varieties) were further considered (Table 7).
24 Signiﬁcantly different forage endpoints identiﬁed in the comparison between soybean 305423 9 40-3-2 and the negative
segregant: ADF (for soybean 305423 9 40-3-2 IHT), ash (for soybean 305423 9 40-3-2 CHT and IHT), carbohydrates (CHT,
IHT), crude ﬁbre (IHT), crude protein (CHT), moisture (IHT), NDF (CHT, IHT). Signiﬁcantly different seed endpoints: ADF
(IHT), carbohydrates (CHT), crude fat (IHT), crude ﬁbre (CHT, IHT), crude protein (CHT, IHT), NDF (CHT, IHT), alanine (CHT,
IHT), aspartic acid (CHT, IHT), glutamic acid (CHT), glycine (CHT, IHT), histidine (IHT), isoleucine (CHT, IHT), leucine (CHT,
IHT), lysine (CHT, IHT), phenylalanine (CHT, IHT), proline (CHT, IHT), serine (CHT, IHT), threonine (CHT, IHT), tryptophan
(CHT, IHT), tyrosine (CHT, IHT), valine (CHT, IHT), calcium (CHT, IHT), magnesium (CHT, IHT), a-tocopherol (CHT, IHT), d-
tocopherol (CHT, IHT), c-tocopherol (CHT, IHT), total tocopherols (CHT, IHT), vitamin B1 (thiamine) (CHT, IHT), vitamin B2
(riboﬂavin) (CHT, IHT), vitamin B3 (niacin) (CHT, IHT), vitamin B5 (pantothenic acid) (CHT, IHT), vitamin B6 (pyridoxine)
(CHT, IHT), daidzein (CHT, IHT), genistin (CHT, IHT), glycitin (CHT, IHT), total genistein (CHT, IHT), total glycitein (CHT, IHT),
stachyose (CHT, IHT), sucrose (CHT, IHT), lectins (CHT, IHT), trypsin inhibitor (CHT, IHT).
25 Signiﬁcantly different forage endpoints identiﬁed in the comparison between soybean 305423 9 40-3-2 and the parental line
soybean 305423: ADF (for soybean 305423 9 40-3-2 CHT), ash (for soybean 305423 9 40-3-2 CHT and IHT), carbohydrates
(CHT, IHT), crude ﬁbre (CHT), crude protein (CHT), NDF (CHT, IHT). Signiﬁcantly different seed endpoints: ash (CHT, IHT),
carbohydrates (IHT), crude fat (IHT), moisture (CHT, IHT), NDF (CHT, IHT), glycine (CHT), histidine (CHT, IHT), leucine
(CHT), methionine (IHT), threonine (CHT, IHT), valine (CHT, IHT), calcium (CHT, IHT), copper (CHT, IHT), iron (CHT, IHT),
magnesium (CHT, IHT), manganese (CHT, IHT), phosphorus (CHT, IHT), potassium (CHT, IHT), zinc (CHT, IHT), d-tocopherol
(CHT, IHT), c-tocopherol (CHT, IHT), total tocopherols (CHT, IHT), vitamin B2 (riboﬂavin) (CHT, IHT), vitamin B3 (niacin)
(CHT, IHT), vitamin B5 (pantothenic acid) (CHT, IHT), vitamin B6 (pyridoxine) (CHT, IHT), vitamin B9 (folic acid) (CHT, IHT),
daidzein (CHT, IHT), daidzin (CHT, IHT), genistin (CHT, IHT), glycitin (CHT, IHT), total daidzein (CHT, IHT), total genistein
(CHT, IHT), total glycitein (CHT, IHT), rafﬁnose (CHT, IHT), stachyose (CHT, IHT), trypsin inhibitor (CHT, IHT).
26 Signiﬁcantly different forage endpoints identiﬁed in the comparison between soybean 305423 9 40-3-2 and the parental line
soybean 40-3-2: ADF (for soybean 305423 9 40-3-2 CHT), carbohydrates (for soybean 305423 9 40-3-2 CHT and IHT), crude
ﬁbre (CHT), crude protein (CHT, IHT), NDF (CHT). Signiﬁcantly different seed endpoints: carbohydrates (CHT), crude fat
(CHT), crude ﬁbre (CHT, IHT), moisture (IHT), alanine (CHT), aspartic acid (CHT, IHT), glycine (CHT), histidine (CHT, IHT),
isoleucine (CHT, IHT), leucine (CHT, IHT), lysine (CHT), phenylalanine (CHT), proline (CHT, IHT), threonine (CHT), tryptophan
(CHT, IHT), tyrosine (CHT), valine (CHT, IHT), calcium (CHT, IHT), magnesium (CHT, IHT), phosphorus (CHT, IHT), potassium
(CHT, IHT), zinc (CHT, IHT), a-tocopherol (CHT, IHT), b-tocopherol (CHT), d-tocopherol (CHT, IHT), c-tocopherol (CHT, IHT),
total tocopherols (CHT, IHT), vitamin B1 (thiamine) (CHT, IHT), vitamin B2 (riboﬂavin) (CHT), vitamin B3 (niacin) (CHT),
vitamin B5 (pantothenic acid) (CHT, IHT), vitamin B6 (pyridoxine) (CHT, IHT), daidzein (CHT, IHT), daidzin (CHT, IHT),
genistin (CHT, IHT), glycitin (CHT, IHT), total daidzein (CHT, IHT), total genistein (CHT, IHT), total glycitein (CHT, IHT),
stachyose (CHT, IHT), sucrose (CHT, IHT), phytic acid (CHT), trypsin inhibitor (CHT, IHT).
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The level of trypsin inhibitor in soybean 305423 9 40-3-2 (CHT and IHT) fell under equivalence
category IV and was signiﬁcantly different (lower) than in Jack and the negative segregant (Table 7).
The results for trypsin inhibitor are consistent with the expected unintended effect that was already
observed for soybean event 305423 (EFSA GMO Panel, 2013). The decrease is caused by silencing of
the endogenous KTi3 gene (encoding a Kunitz trypsin inhibitor), and is therefore also expected to
occur in the context of the stack. A decreased level of trypsin inhibitor is not posing any food and feed
safety concern.
The GMO Panel assessed all the signiﬁcant differences, and any lack of equivalence, for the
remaining endpoints in Table 7. After considering their well-known biological role and the magnitudes
of the changes observed, the GMO Panel did not identify any need for further food/feed safety
assessment.
3.4.4. Conclusion
The GMO Panel concludes that soybean 305423 9 40-3-2 differs from the non-GM comparator Jack
and the negative segregant, and is not equivalent to the non-GM soybean reference varieties, in
having an altered fatty acid proﬁle. The changes in fatty acid proﬁle are consistent with those
observed in the single-event soybean 305423, including the increase in oleic acid content
(the intended trait). The altered fatty acid proﬁle is assessed in Section 3.5.5. No further assessment
Table 7: Compositional endpoints that are further assessed based on the results of the statistical analysis: means (for
the two-event stack soybean 305423 9 40-3-2 and the four comparators) and equivalence limits (from the
non-GM reference varieties) estimated from the 2011 ﬁeld trials (Table 5)
Endpoint
Soybean
305423 3 40-3-2
Comparator
Equivalence
limits
from non-GM
reference
varieties
CHT(a) IHT(b) Jack
Negative
segregant
Soybean
305423
Soybean 40-3-2
Seed constituents
ADF
(% dw)
15.7 15.9 15.4(c) 15.3(c) 15.9(c,d) 16.2(c,d) Not applied
Calcium
(mg/kg dw)
2,260 2,250 2,560 2,580 2,360 2,400 (2,320, 2,740)
Zinc
(mg/kg dw)
51.7 51.6 54.2 50.6 57.1(c,d) 49.5 (41.6, 49.5)
Riboﬂavin
(mg/kg dw)
3.95 3.87 3.56 3.55 3.70 3.80(d) (3.14, 3.82)
Glycitin
(mg/kg dw)
283 289 310 208 423 166 (143, 280)
Total
glycitein
(mg/kg dw)
183 187 200 135 272 108 (93.4, 181)
Trypsin
inhibitor
(TIU/mg dw)
18.1 18.7 29.4 30.8 13.8 30.8 (26.2, 38.7)
Forage constituents
Crude ﬁbre
(% dw)
30.2 29.2 30.3(c) 30.4(c) 28.8(d) 29(d) Not applied
The outcome of the test of difference is shown in the entries for the comparators: entries that are not signiﬁcantly different from the stack (CHT, IHTor
both) are marked with upper indices(c),(d),(c,d); for entries with no indices, the stack (CHT/IHT) is signiﬁcantly different from the comparator. The
outcome of the test of equivalence is shown in the entries for the stack, and it is differentiated by greyscale backgrounds: white (the equivalence test
was not performed), light grey (equivalence category III) and dark grey (equivalence category IV).
dw: dry weight; TIU: trypsin inhibitor units.
(a): Treated with conventional herbicides (quizalofop p-ethyl and fomesafen).
(b): Treated with the intended herbicides (chlorimuron, thifensulfuron and glyphosate).
(c): No signiﬁcant difference identiﬁed between 305423 9 40-3-2 (CHT) and the comparator.
(d): No signiﬁcant difference identiﬁed between 305423 9 40-3-2 (IHT) and the comparator.
(c,d): No signiﬁcant differences identiﬁed between 305423 9 40-3-2 (both CHT and IHT) and the comparator.
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for food and feed safety was needed for the other differences, or any other lack of equivalence,
identiﬁed in the composition and in the agronomic and phenotypic characteristics of soybean
305423 9 40-3-2. The comparison with the two parental lines did not reveal any potential interaction
that could be of concern for food and feed safety.
The differences in agronomic and phenotypic characteristics identiﬁed between soybean
305423 9 40-3-2 and the four comparators are further discussed for their potential environmental
impact in Section 3.6.
3.5. Food and feed safety assessment
3.5.1. Effect of processing27
Soybean 305423 9 40-3-2 will undergo the existing methods of production and processing used for
commercial soybean. No novel methods of production and processing are envisaged.
Seeds of soybean 305423 9 40-3-2 collected from the 2011 ﬁeld trials (Table 5) were processed
into reﬁned bleached deodorised (RBD) oil and analysed for fatty acid composition.28 The GMO
Panel concluded that the fatty acid proﬁle of RBD oil obtained from soybean 305423 9 40-3-2 was
similar to the fatty acid proﬁle of unprocessed seeds (Table 8). This was also previously noted for
soybean 305423 (EFSA GMO Panel, 2013).
Table 8: Mean values of fatty acid levels in seed oil and RBD oil29 from 305423 9 40-3-2
Soybean 305423 3 40-3-2 (IHT(a))
Fatty acids (% total FA) Seed oil(b) RBD oil(c)
Saturated fatty acids
Myristic acid (C14:0) 0.0484 0.00
Palmitic acid (C16:0) 6.17 6.20
Heptadecanoic acid (C17:0) 0.783 0.75
Stearic acid (18:0) 4.40 3.88
Arachidic acid (C20:0) 0.428 0.41
Heneicosanoic acid (C21:0) 0.0639 0.00
Behenic acid (C22:0) 0.406 0.46
Tricosanoic acid (C23:0) 0.0688 0.00
Lignoceric acid (C24:0) 0.180 0.202
Monounsaturated fatty acids
Palmitoleic acid (C16:1) 0.116 0.10
Heptadecenoic acid (C17:1) 1.23 1.35
Oleic acid (C18:1) 74.8 74.7
Nonadecenoic acid (C19:1) isomer 1 0 0.36
Nonadecenoic acid (C19:1) isomer 2 0.304 0.31
Eicosenoic acid (C20:1) 0.361 0.38
n-3 polyunsaturated fatty acids
(9,15) isomer of linoleic acid (C18:2) 0.752 0.645
a-Linolenic acid (C18:3) 5.18 4.96
n-6 polyunsaturated fatty acids
Linoleic acid (C18:2) 4.17 3.76
RBD: reﬁned bleached deodorised; FA: fatty acid.
(a): Treated with the intended herbicides (chlorimuron, thifensulfuron and glyphosate).
(b): Mean values extracted from (Table 6).
(c): Average (rounded) of the values for two pooled samples of RBD oil. The two samples were produced combining seeds from
two non-overlapping sets of ﬁve trials sites.
27 Dossier: Part I – Section A3.5.
28 Additional information: 9/9/2014 and 29/6/2015.
29 Additional information: 29/6/2015.
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3.5.2. Toxicology
3.5.2.1. Toxicological assessment of newly expressed proteins
Two proteins (GM-HRA and CP4 EPSPS) are newly expressed in the two-event stack soybean
305423 9 40-3-2.
The GMO Panel has previously assessed these proteins in the context of the single events (Table 1),
as well as in other soybean events (EFSA GMO Panel 2011d, 2012b) and no safety concern for humans
or animals was identiﬁed. The GMO Panel is not aware of any new information that would change
these conclusions. Updated bioinformatic studies5 conﬁrmed the absence of relevant similarities
between these newly expressed proteins to known toxins.
The potential for a functional interaction of these newly expressed proteins in two-event stack
soybean 305423 9 40-3-2 has been assessed with regard to human and animal health. The two
proteins are enzymes which catalyse distinct biochemical reactions and act on unrelated substrates in
the plant. No reasons were identiﬁed to expect that the presence of the two proteins in combination
would result in interactions producing effects different from those of the individual proteins
(Section 3.3). As the individual proteins are considered safe for humans and animals, the same
conclusion can be extended to their presence in the two-event stack soybean 305423 9 40-3-2.
The GMO Panel concludes that there are no safety concerns to human and animal health related to
GM-HRA and CP4 EPSPS proteins newly expressed in soybean 305423 9 40-3-2.
3.5.2.2. Toxicological assessment of components other than newly expressed proteins
The compositional analysis of soybean 305423 9 40-3-2 conﬁrmed the expected altered fatty acid
proﬁle in seeds and oil (Table 8). All of these fatty acids occur naturally in the diet of humans and
animals. The safety impact of the altered fatty acid proﬁle of soybean 305423 9 40-3-2 is evaluated in
Section 3.5.5.
3.5.3. Animal studies with the food/feed derived from GM plants
3.5.3.1. Subchronic feeding study in rats5
The applicant provided a publication (Qi et al., 2012) describing a subchronic study in rats fed diets
containing up to 30% raw ﬂour from soybean 305423 9 40-3-2 or from a non-GM soybean. An
additional group was fed a commercial diet not containing soybean ﬂour or meal. Diets are reported to
be nutritionally balanced (Chinese standard NY/T1102-2006). The GMO Panel notes that limited
information is provided on the study design, material and methods and results, as well as on its GLP
compliance status. The GMO Panel also notes the low number of experimental units per group (two
per sex) and considers that an appropriate statistical analysis of the data to draw relevant conclusions
is not possible in this study.
The GMO Panel considers that a subchronic feeding study in rodents on soybean 305423 9 40-3-2
is not needed on the basis of the molecular characterisation and comparative assessment.
3.5.3.2. 42-day feeding study in chickens for fattening
A 42-day feeding study with a total of 720 (half male and half female) chickens for fattening
(1-day-old Ross x Cobb) was provided.30 The birds were randomly allocated to six dietary treatment
groups with 120 chicks per treatment (12 pens per treatment, six pens for males and six for females,
10 birds per pen). Birds were fed diets containing soybean 305423 9 40-3-2 (conﬁrmed by real-time
PCR, treated and not treated with the intended herbicides), and compared with those fed diets
containing a negative segregant (generation BC1F7
31) or three non-GM commercial varieties (93B86,
93B15 and 93M40). Diets were prepared containing equal quantities of defatted toasted soybean meal
(26.5% in the starter phase diet, 23% in the grower phase diet, 21.5% in the ﬁnisher phase diet),
soybean hull (1% in all phase diets) and soybean oil (0.5% in all phase diets), together with maize
and other minor constituents. Before feed formulation, all soybean varieties were analysed for
proximates, ﬁbre fractions, minerals, amino acids, fatty acids and mycotoxins. The GM-HRA and CP4
EPSPS proteins were not detected in the toasted meal or hull.32 The diets were isonitrogenous and
30 Dossier: Part I – Annex 7.
31 Additional information: 4/12/2013.
32 Lower limit of quantiﬁcation: 0.27 ng/mg.
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isocaloric (conﬁrmed by analysis). The starter phase diets (about 22% crude protein (CP), 3,124 kcal
metabolisable energy (ME)/kg) were given until day 21, grower phase diets (about 20% CP, 3,151 kcal
ME/kg) from day 22 to day 35, and ﬁnisher phase diets (about 18% CP, 3,175 kcal ME/kg) from day
36 until the end. Feed in mash form and water were provided to the birds for ad libitum intake.
Chickens were observed three times daily for clinical signs; deaths were recorded and necropsy
performed on all birds found dead. Body weight and feed intake were measured every 7 days. At the
end four birds per pen were taken for carcass evaluation (yield, dressing percentage, weight of thighs,
breast, wings, legs, abdominal fat, kidney and whole liver). Performance and carcass trait tolerance
intervals were constructed using data from the three groups of animals fed diets containing the non-GM
commercial varieties. Differences between the control and 305423 9 40-3-2 groups (treated or not
treated with the intended herbicides) were evaluated to determine if observed values were contained
within the respective interval. The individual bird (not the pen) was considered as the experimental unit.
Overall mortality was low (< 2%) with no relevant difference between the groups. Overall no
signiﬁcant difference was seen in ﬁnal body weight (about 1.9 kg) or feed:gain ratio (about 1.86)
between the soybean 305423 9 40-3-2 and the negative segregant group. No signiﬁcant differences
were observed in carcass yield. All performance and carcass data fell within the conﬁdence intervals
established by the reference groups.
In recognition that a negative segregant is of limited value when used as control, the applicant
provided another study31 with the same design, in which the non-GM comparator Jack was compared
to another GM soybean and to the same three commercial varieties used in the ﬁrst study. No
signiﬁcant differences were observed for mortality (< 2%), performance parameters (ﬁnal body weight
ca. 1.9 kg, feed:gain ratio ca. 1.87), or carcass yield between Jack and the three commercial varieties.
The applicant concluded that since both the GM soybean 305423 9 40-3-2 and its comparator Jack,
albeit tested at different times, did not differ signiﬁcantly from the three commercial varieties, no
difference would be expected between the GM soybean 305423 9 40-3-2 and Jack.
The GMO Panel considers that a feeding study in chickens for fattening, in which material derived
from a negative segregant is administered as the sole control material, has limitations, principally
because of an inability to detect unintended effects. However, the GMO Panel accepts that the two
studies taken in conjunction provide evidence that the defatted toasted GM soybean meal
305423 9 40-3-2 is as nutritious as non-GM soybean varieties.
3.5.4. Allergenicity
For allergenicity assessment, a weight-of-evidence approach is followed, taking into account all of
the information on the newly expressed proteins, since no single piece of information or experimental
method yields sufﬁcient evidence to predict allergenicity (EFSA, 2006; Codex Alimentarius, 2009). In
addition, when known functional aspects of the newly expressed protein or structural similarity to
known adjuvants may indicate an adjuvant activity, the possible role of these proteins as adjuvants is
considered. When newly expressed proteins with a potential adjuvant activity are expressed together,
possible interactions increasing adjuvanticity and impacting the allergenicity of the GM crop are
assessed.
3.5.4.1. Assessment of allergenicity of the newly expressed proteins33
For allergenicity, the GMO Panel has previously evaluated the safety of the GM-HRA and CP4 EPSPS
proteins, and no concerns on allergenicity were identiﬁed in the context of the applications assessed
(Table 1). No new information on allergenicity of the newly expressed GM-HRA and CP4 EPSPS
proteins that might change the previous conclusions of the GMO Panel has become available. Based on
current knowledge, and as none of the newly expressed proteins showed allergenicity, no reasons for
concern regarding the simultaneous presence of these newly expressed proteins in this stack soybean
affecting allergenicity were identiﬁed.
For adjuvanticity, no information available on the structure or function of the newly expressed
GM-HRA and CP4 EPSPS proteins would suggest an adjuvant effect of the individual proteins or their
simultaneous presence in soybean 305423 9 40-3-2 resulting in or increasing an eventual
immunoglobulin E (IgE) response to a bystander protein.
33 Dossier: Part I – Section D7.9.1; additional information: 16/4/2015.
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3.5.4.2. Assessment of allergenicity of the whole GM plant34
Soybean is considered to be a common allergenic food35 (OECD, 2012). Therefore, any potential
change in the endogenous allergenicity of the GM plant when compared with that of its comparator(s)
should be assessed (EFSA, 2006). Such assessments were performed for the single-event soybeans
305423 and 40-3-2, and no reasons for concern were identiﬁed by the GMO Panel (Table 1).
At the request of the GMO Panel, the applicant provided an assessment of the endogenous
allergenicity of soybean 305423 9 40-3-2.36 Speciﬁcally, the applicant performed two-dimensional
electrophoresis of protein extracts of soybean 305423 9 40-3-2, its non-GM comparator and two non-
GM commercial soybean reference varieties followed by western blotting using individual sera from 10
humans allergic/sensitised to soybean. This study showed no meaningful differences in the IgE-binding
patterns between the extracts of proteins derived from soybean 305423 9 40-3-2, the non-GM
comparator Jack and non-GM reference varieties. In addition, ELISA studies were also carried out
using individual sera from 11 humans allergic/sensitised to soybean which conﬁrmed the outcome of
the previous study.
The GMO Panel considers that there is no evidence that the genetic modiﬁcation might signiﬁcantly
change the overall allergenicity of soybean 305423 9 40-3-2 when compared with that of its non-GM
comparator and non-GM commercial soybean reference varieties.
3.5.5. Nutritional assessment of GM food/feed
3.5.5.1. Human nutritional assessment
The main product for human consumption from soybean is the oil. The GMO Panel already
assessed the nutritional consequences of the fatty acid proﬁle modiﬁcations related to 305423 (EFSA
GMO Panel, 2013). The fatty acid proﬁle of soybean seeds 305423 9 40-3-2 is similar to that of
soybean seeds 305423 (Section 3.4.3 and Table 6).37 The fatty acid proﬁle of the RDB oil of soybean
305423 9 40-3-2 is essentially the same as that of the unprocessed seeds (Table 8). Consequently,
the GMO Panel concludes that the basis for the nutritional assessment made for soybean 305423 can
also be used for soybean 305423 9 40-3-2.
The assessment of dietary exposure38 embraced all possible uses of soybean 305423 9 40-3-2 oil,
including both commercial and domestic uses of the oils.39 Consumption data were taken from the UK
National Diet and Nutrition Survey 2008-2010 (Bates et al., 2011). The subpopulations considered
were toddlers (1–3 years), children (4–10 years), teenagers (11–18 years), adults (19–64 years) and
elderly (≥ 65 years). The estimated dietary intakes (expressed as percentage of energy (E %) of
the total diet) of fatty acid groups (saturated fatty acids (SFA), monounsaturated fatty acids (MUFA),
cis-n-3 PUFA and cis-n-6 PUFA (polyunsaturated fatty acids), trans fatty acids (TFA)) were based on
the fatty acid composition of the unprocessed seeds of herbicide-treated soybean 305423 9 40-3-2
estimated in the ﬁrst statistical comparative analysis of the 2011 ﬁeld trials (Section 3.4.1), using three
substitution levels (100%, 50% and 25%) of vegetable oils40 with soybean 305423 9 40-3-2 oil. The
GMO Panel selected the 100 % substitution as the most conservative scenario arising from both
domestic and commercial use of the vegetable oils.
Calculations based on the full replacement scenario projected that fatty acid intakes would be
increased for MUFA and cis-n-3 PUFA, reduced for cis-n-6 PUFA, slightly reduced for SFA, and
unchanged for TFA (Table 9).
Similar changes were previously seen for soybean 305423 oil (EFSA GMO Panel, 2013). As in that
case, the assessment of the nutritional impact of soybean 305423 9 40-3-2 oil is that these projected
changes are generally small and would not impact on health and nutrition for average and high
consumers of vegetable oils.
34 Dossier: Part I – Section D7.9.2; additional information: 3/7/2014 and 14/4/2015.
35 Directive 2007/68/EC of the European Parliament and of the Council of 27 November 2007 amending Annex IIIa to Directive
2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. OJ L 310, 27.11.2007, p. 11–
14.
36 Additional information: 3/7/2014 and 16/4/2015.
37 Additional information: 22/4/2014, 1/2/2016 and 19/5/2016.
38 Spontaneous additional information: 30/7/2015.
39 Food items considered are the targeted foods (fried ﬁsh, meat, potatoes, vegetables and other fried foods, savoury snacks
and crackers) and other foods (salad dressings, margarines and spread, mayonnaise and home use of vegetable oils).
40 Conventional soybean, rapeseed and sunﬂower oils. These three oils account for about 80% of vegetable oils available for
consumption in the UK.
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Dietary intake data for low consumers of vegetable oils (not available at the time of assessment of
soybean 305423 oil) were provided in the context of this application. Thus, it was possible to assess
dietary intakes and nutritional impacts for consumers of vegetable oils also at the low (5th) centile of
vegetable oil intake when all vegetable oil is replaced by 305423 9 40-3-2 oil (full replacement scenario,
Table 9). In the full replacement scenario, the estimated dietary intake for consumers of vegetable oils at
the low (5th) centile of vegetable oil intake indicated that although a decrease in the intake of n-6 PUFA
occurs in both male and females in all age groups, the resultant intakes would still exceed 1 E%
(Table 9), which is the level below which clinical symptoms of linoleic deﬁciency have been observed
(EFSA NDA Panel, 2010).
The GMO Panel noted that in the ﬁnal statistical comparative analysis of the 2011 ﬁeld trials (Section
3.4.1, 3.4.3)41 some of the estimated mean values of the fatty acid levels for soybean 305423 9 40-3-2
seeds changed with respect to the estimates used for the exposure assessment. The GMO
Table 9: Estimated daily intake (E%) of fatty acid groups before (B) and after (A) the replacement
Fatty acid group
Males Females
5th % 50th % 95th % 5th % 50th % 95th %
B A B A B A B A B A B A
Toddlers (1–3 years)
SFA 8.9 8.9 14.7 14.4 20.6 20.1 10.2 9.4 14.8 14.5 19.7 19.4
MUFA 7.8 8.5 11.3 14.6 14.5 21.9 7.4 9.3 11.4 15.2 14.8 22.3
n-3 PUFA 0.4 0.5 0.7 1.3 1.1 3.3 0.4 0.5 0.7 1.5 1.3 4.0
n-6 PUFA 2.3 1.8 3.9 2.9 6.8 4.3 2.4 1.8 4.1 2.8 6.0 4.3
TFA 0.3 0.3 0.7 0.7 1.3 1.3 0.5 0.4 0.7 0.7 1.0 1.0
Children (4–10 years)
SFA 9.3 9.1 13.4 13.1 18.0 18.0 9.1 8.8 13.3 13.0 17.7 17.6
MUFA 8.6 10.1 11.9 16.7 15.2 24.7 8.7 10.2 12.2 17.2 15.9 27.0
n-3 PUFA 0.5 0.6 0.8 1.6 1.3 3.2 0.5 0.6 0.9 1.7 1.4 3.8
n-6 PUFA 2.7 2.1 4.4 3.2 6.6 4.4 2.8 2.2 4.6 3.3 6.7 5.0
TFA 0.4 0.4 0.7 0.7 1.0 1.0 0.4 0.4 0.7 0.7 1.2 1.2
Teenagers (11–18 years)
SFA 8.4 8.3 12.5 12.3 16.9 16.8 7.7 7.5 12.4 12.2 16.5 16.2
MUFA 8.8 11.1 12.5 17.7 16.2 26.3 8.3 10.2 12.9 19.4 16.8 31.8
n-3 PUFA 0.5 0.7 0.9 1.9 1.5 5.9 0.5 0.7 1.0 2.1 1.7 5.1
n-6 PUFA 3.2 2.2 4.8 3.4 6.9 5.0 2.8 2.1 4.9 3.4 7.3 5.3
TFA 0.4 0.4 0.7 0.7 1.1 1.1 0.4 0.4 0.8 0.7 1.1 1.1
Adults (19–64 years)
SFA 6.4 6.4 12.1 11.8 18.4 17.9 6.8 6.9 12.1 11.8 17.5 17.2
MUFA 6.8 8.4 11.9 16.1 16.5 24.0 6.4 8.1 11.6 15.7 16.1 24.0
n-3 PUFA 0.5 0.5 1.0 1.4 1.8 3.4 0.5 0.6 1.0 1.6 1.9 3.3
n-6 PUFA 2.6 2.0 4.8 3.4 7.3 5.2 2.7 1.9 4.9 3.5 7.8 5.9
TFA 0.3 0.3 0.7 0.7 1.2 1.2 0.3 0.3 0.7 0.7 1.2 1.2
Elderly (≥ 65 years)
SFA 8.3 8.0 13.8 13.5 19.6 19.3 7.4 7.1 14.0 13.8 20.2 20.7
MUFA 8.6 9.2 11.9 15.3 15.6 22.9 8.3 9.1 11.7 14.7 15.9 22.7
n-3 PUFA 0.6 0.6 1.1 1.4 2.0 3.0 0.5 0.6 1.1 1.3 2.1 2.4
n-6 PUFA 2.4 2.2 4.8 3.4 7.3 4.8 2.7 2.2 4.8 3.5 7.5 5.6
TFA 0.4 0.4 0.9 0.8 1.4 1.4 0.4 0.4 0.8 0.8 1.3 1.3
SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; TFA: trans fatty acids.
Predicted changes in the total diet with respect to fatty acid groups (SFA, MUFA, PUFA, TFA) through replacement of all
consumed vegetable oils (rapeseed, sunﬂower, blended vegetable oils) by soybean 305423 9 40-3-2 oil are given as percentage
of total energy in different age groups for the 5th, 50th and 95th centile consumers.
41 Additional information: 19/5/2016.
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Panel concluded that the relative proportions of SFA, MUFA, n-3 and n-6 PUFA, and of TFA obtained in
the two different statistical analyses are essentially identical. Considering that former analyses have
demonstrated that the fatty acid pattern of the soybean seed is reﬂected in the RBD oil derived from
the seed, the GMO Panel concludes that a new exposure assessment with repeated substitution
scenarios is not needed. The GMO Panel also notes that the estimated content of linoleic acid and
(9,15) isomer of linoleic acid are higher in the ﬁnal analysis compared to the ﬁrst analysis (from 3.76%
FA to 4.17% FA and from 0.645% FA to 0.752% FA, respectively). Therefore, 305423 9 40-3-2
soybean seed is even less likely to induce linoleic acid deﬁciency in low consumers of vegetable oils with
complete substitution by 305423 9 40-3-2 soybean oil.
In conclusion, the proﬁle of fatty acid intake, after substituting soybean 305423 9 40-3-2 oil for
conventional vegetable oils, should not have adverse impact on consumer’s health and nutrition
regarding four fatty acids groups (SFA, MUFA, n-3 PUFA and TFA). Changes in n-6 PUFA might give
rise to concern, given the proximity of the intake values for low consumers to the level below which
deﬁciency of linoleic acid (the main dietary fatty acid of the n-6 PUFA group) might occur. However,
considering the conservative nature of the full replacement scenario in the consumer group with the
lowest consumption of vegetable oils in the exposure assessment, the size of the observed differences
would not be expected to introduce adverse effects on human health with respect to n-6 PUFA intake.
Other soybean products for human consumption (for example, lecithin42) are not expected to differ
in their composition, except for their fatty acid content. The contribution of fatty acids from such
products to overall human exposure would be small and is not expected to affect the conclusion on
human health and nutrition.
3.5.5.2. Animal nutritional assessment
Defatted toasted soybean meal represents the most common soybean by-product used in animal
feed formulations, with around 90% of the defatted toasted soybean meal entering the feed chain in
the EU mainly to poultry, pig and cattle. Presently only small amounts of full fat soybeans (1% of the
total soybean feed) are directly fed to food-producing animals. The use of soybean oil in animal feed is
limited and only small amounts (0.5–3%) are added to mixed feed (especially for poultry and pigs) in
order to avoid dust, improve the quality/stability of pellets and add energy to the diets.43
Compositional data indicates that the defatted toasted soybean meal from soybean 305423 9 40-3-2
is expected to deliver the same nutrition as its non-GM comparator and other non-GM commercial
varieties. This is consistent with the assessment of the single event 305423 (EFSA GMO Panel, 2013) and
was conﬁrmed by the results of a feeding study in chickens for fattening (Section 3.5.3).
3.5.6. Conclusion
The safety assessment identiﬁed no concerns regarding the potential toxicity and allergenicity of
the proteins GM-HRA and CP4 EPSPS, newly expressed in soybean 305423 9 40-3-2, and found no
evidence that the genetic modiﬁcation might signiﬁcantly change the overall allergenicity of soybean
305423 9 40-3-2. Nutritional assessment of soybean 305423 9 40-3-2 oil and oil-containing food
products did not identify concerns for human health and nutrition. The contribution of fatty acids from
soybean 305423 9 40-3-2 in other soybean products to overall human exposure would be small and is
not expected to affect the conclusion on human health and nutrition. Based on the assessment of the
single event 305423, on compositional data for soybean 305423 9 40-3-2, and on the results of a
feeding study in chickens for fattening, the GMO Panel concludes that feedingstuffs derived from
defatted toasted 305423 9 40-3-2 soybean meal are safe and as nutritious as those derived from
other non-GM soybean varieties.
3.6. Environmental risk assessment
3.6.1. Evaluation of relevant scientiﬁc data
Considering the scope of application EFSA-GMO-NL-2007-47 (which excludes cultivation), the
environmental risk assessment (ERA) of soybean 305423 9 40-3-2 is mainly concerned with: (1) the
exposure of bacteria to recombinant DNA in the gastrointestinal tract of animals fed GM material and
bacteria present in environments exposed to their faecal material (manure and faeces); and (2) the
42 Additional information: 24/7/2014.
43 Deutscher Verband f€ur Tiernahrung, personal communication, 29/7/2011.
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accidental release into the environment of viable soybean 305423 9 40-3-2 seeds during
transportation and processing (EFSA GMO Panel, 2010a).
3.6.2. Persistence and invasiveness of the GM plant44
Cultivated soybean (Glycine max (L.) Merr.) is a species in the subgenus Soja of the genus Glycine.
The species originated from eastern Asia and is a highly domesticated crop (Lu, 2005). Cultivated
soybean seeds rarely display any dormancy characteristics and can grow as volunteers in the year
after cultivation only under certain environmental conditions. If volunteers occur, they do not compete
well with the succeeding crop, and can easily be controlled mechanically or chemically (OECD, 2000).
The presence of volunteers of G. max was occasionally reported in some areas of Italy where soybean
is intensively cultivated (Celesti-Grapow et al., 2010). However, soybean seeds usually do not survive
during the winter owing to management practices prior to planting the subsequent crop (Owen, 2005).
Also, survival of soybean plants outside cultivation areas is limited mainly by a combination of low
competitiveness, the absence of a dormancy phase and susceptibility to plant pathogens and cold
climatic conditions.
The applicant presented agronomic and phenotypic data on soybean 305423 9 40-3-2 gathered
from ﬁeld trials conducted in soybean growing areas in North America (Section 3.4.1). The data
showed differences with the non-GM comparator and the three additional comparators (the negative
segregant and the two parental lines, soybean 305423 and soybean 40-3-2) for several endpoints and
equivalence with the non-GM reference varieties for all the endpoints. Due to the low survival capacity
of soybean, the observed differences are unlikely to change the ﬁtness (e.g. survival, fecundity,
competitiveness) or invasiveness characteristics of soybean 305423 9 40-3-2 plants.
It is considered very unlikely that soybean 305423 9 40-3-2 will differ from conventional soybean
varieties in its ability to survive until subsequent seasons, or to establish occasional feral plants under
European environmental conditions in case of accidental release into the environment of viable
soybean 305423 9 40-3-2 seeds during transportation and processing.
The expected change in seed fatty acid composition in soybean 305423 9 40-3-2 resulting from
the newly inserted gm-fad2-1 gene (encoding the D6 desaturase protein from G. max) is not known to
provide a potential agronomic advantage. The gm-hra and CP4 epsps genes coding for herbicide
tolerance traits can provide a potential selective advantage for this GM soybean plant when
glyphosate-based and ALS-inhibiting herbicides are applied. However, in case of accidental release
intro the environment of viable soybean 305423 9 40-3-2 seeds during transportation and processing,
establishment and survival of this GM soybean in the EU is limited by the biotic and abiotic factors
described above.
The GMO Panel is not aware of any scientiﬁc report of increased survival capacity, including
overwintering, of existing GM soybeans varieties (Dorokhov et al., 2004; Owen, 2005; Bagavathiannan
and Van Acker, 2008; Lee et al., 2009). Therefore, the GMO Panel is of the opinion that the likelihood
of environmental effects of soybean 305423 9 40-3-2 in Europe will not be different from that of
conventional soybean varieties.
3.6.3. Effects of gene transfer45
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through horizontal gene transfer of DNA or through vertical gene ﬂow via cross-
pollination from ﬂowering plants arising from spilled seed.
1) Plant-to-microorganism gene transfer5
The potential for horizontal gene transfer of the recombinant DNA of the single events has already
been assessed in previous opinions (see Table 1) and no concern for an unlikely, but theoretically
possible, horizontal gene transfer of the recombinant genes to bacteria in the gut or other receiving
environments was identiﬁed.
Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for horizontal gene transfer or a selective
advantage, were not identiﬁed.
44 Dossier: Part I – Section D9.1; additional information: 1/2/2016 and 19/5/2016.
45 Dossier: Part I – Section D9.3.
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Therefore, in line with its previous assessments of soybean events 305423 and 40-3-2, the GMO
Panel concludes that the horizontal gene transfer from soybean 305423 9 40-3-2 to bacteria is highly
unlikely, theoretically possible but does not raise a safety concern.
2) Plant-to-plant gene transfer
Considering the scope of application EFSA-GMO-NL-2007-47 and the biology of soybean, a possible
pathway to harm is the potential of occasional feral GM soybean plants originating from seed import
spills to transfer recombinant DNA to sexually cross-compatible plants.
The genus Glycine is divided into two distinct subgenera: Glycine and Soja. The subgenus Glycine
contains 16 perennial wild species, while the cultivated soybean, G. max, and its wild and semiwild
annual relatives, G. soja and G. gracilis, are classiﬁed in the subgenus Soja (OECD, 2000). Owing to
the low level of genomic similarity among species of the genus Glycine, G. max can cross only with
other members of Glycine subgenus Soja under natural conditions (Singh et al., 1987; Hymowitz et al.,
1998; Lu, 2005). Hence, the three species of the subgenus Soja are capable of cross-pollination and
the hybrid seed that is produced can germinate normally and produce plants with fertile pollen and
seed (Abe et al., 1999; Nakayama and Yamaguchi, 2002). Since G. soja and G. gracilis are indigenous
to China, Taiwan, Korea, Japan, the far east region of Russia, Australia, the Philippines and the South
Paciﬁc, and since they have not been reported in other parts of the world where cultivated soybean is
grown (Dorokhov et al., 2004; Lu, 2005), the plant-to-plant gene transfer from soybean is restricted to
cultivated areas and the occasional soybean plants resulting from seed spillage in the EU.
Soybean is an annual, almost completely self-pollinating crop with a percentage of cross-pollination
usually below 1% (OECD, 2000; Ray et al., 2003; Lu, 2005; Yoshimura et al., 2006; Abud et al., 2007).
Soybean pollen dispersal is limited because it has strong tendency to produce cleistogamous ﬂowers
(the anthers mature in the bud and directly pollinate the stigma of the same ﬂower (OECD, 2000)).
However, cross-pollination rates as high as 6.3% have been reported for closely spaced plants (Ray
et al., 2003), suggesting the potential for some within-crop gene ﬂow in soybean. These results
indicate that natural cross-pollination rates can ﬂuctuate signiﬁcantly among different soybean varieties
under particular environmental conditions such as a favourable climate for pollination and an
abundance of pollinators (Gumisiriza and Rubaihayo, 1978; Kikuchi et al., 1993; Ahrent and Caviness,
1994; Ray et al., 2003; Lu, 2005).
For plant-to-plant gene transfer to occur, imported soybean 305423 9 40-3-2 seeds need to be
processed outside the importing ports, transported into regions of soybean production in Europe,
spilled during transportation, germinate and develop into plants in the very close vicinity of soybean
ﬁelds, and there needs to be an overlap of ﬂowering periods and environmental conditions favouring
cross-pollination. It must be noted that most soybean 305423 9 40-3-2 seeds are processed in the
countries of production or in ports of importation. The overall likelihood of cross-pollination between
occasional feral GM soybean plants and cultivated soybean is therefore extremely low.
In conclusion, even if cross-pollination would occur, the GMO Panel is of the opinion that the
likelihood of environmental effects as a consequence of spread of genes from occasional feral soybean
plants in Europe will not differ from that of conventional soybean varieties (see Section 3.6.2).
3.6.4. Interactions of the GM plant with target organisms46
Considering the scope of application EFSA-GMO-NL-2007-47, and the absence of target pests,
potential interactions of the GM plant with target organisms are not considered a relevant issue by the
GMO Panel.
3.6.5. Interactions of the GM plant with non-target organisms47
Considering the scope of application EFSA-GMO-NL-2007-47, and the low level of exposure to the
environment, potential interactions of spilled seeds or occasional feral soybean 305423 9 40-3-2
arising from seed import spills with non-target organisms are not considered a relevant issue by the
GMO Panel.
46 Dossier: Part I – Section D9.4.
47 Dossier: Part I – Section D9.5.
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3.6.6. Interactions with the abiotic environment and biogeochemical cycles48
Considering the scope of application EFSA-GMO-NL-2007-47, and the low level of exposure to the
environment, potential interactions of spilled seeds or occasional feral soybean 305423 9 40-3-2
arising from seed import spills with the abiotic environment and biogeochemical cycles are not
considered a relevant issue by the GMO Panel.
3.6.7. Conclusion
In the case of accidental release into the environment of viable seeds of soybean 305423 9 40-3-2,
there are no indications of an increased likelihood of the establishment and spread of occasional feral
soybean 305423 9 40-3-2 plants, unless these plants are exposed to ALS-inhibiting or glyphosate-
based herbicides
Considering the scope of the application EFSA-GMO-NL-2007-47, interactions of soybean
305423 9 40-3-2 with the biotic and abiotic environment are not considered to be relevant issues. The
unlikely but theoretically possible transfer of the recombinant genes from soybean 305423 9 40-3-2 to
bacteria does not raise a safety concern for these bacteria owing to the lack of a selective advantage.
Therefore, considering the introduced traits, the outcome of the comparative analysis, the routes of
exposure and the limited exposure levels, the GMO Panel concludes that soybean 305423 9 40-3-2
would not raise safety concerns in the event of accidental release of viable GM soybean seeds into the
environment.
3.7. Post-market monitoring
3.7.1. Post-market monitoring of GM food/feed
Considering the intended, altered nutritional composition of soybean 305423 9 40-3-2, a proposal
for a post-market monitoring (PMM) plan needs to be provided by the applicant (EFSA GMO Panel,
2011a).
For speciﬁc labelling, the applicant proposed that, for example, operators handling products
containing or consisting of oil produced from soybean 305423 9 40-3-2 shall be required to label
these products with the words ‘genetically modiﬁed soybean with altered fatty acid proﬁle’.49 The GMO
Panel considers that this proposal is consistent with the compositional data provided for this soybean.
3.7.2. Post-market environmental monitoring50
The objectives of a post-market environmental monitoring (PMEM) plan, according to Annex VII of
Directive 2001/18/EC are to: (1) conﬁrm that any assumption regarding the occurrence and impact of
potential adverse effects of the GMO, or its use, in the environmental risk assessment are correct; and
(2) identify the occurrence of adverse effects of the GMO, or its use, on human health or the
environment that were not anticipated in the ERA.
Monitoring is related to risk management, and thus a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc content of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
The PMEM plan proposed by the applicant includes: (1) the description of a monitoring approach
involving operators (federations involved in soybean import and processing), reporting to the
applicants, via a centralised system, any observed adverse effect(s) of GMOs on human health and the
environment; (2) a coordinating system established by EuropaBio for the collection of information
recorded by the various operators (Lecoq et al., 2007; Windels et al., 2008); and (3) the use of
networks of existing surveillance systems. The applicant proposes to submit a PMEM report on an
annual basis and a ﬁnal report at the end of the consent period. The GMO Panel considers that the
scope of the post-market environmental monitoring plan provided by the applicant is consistent with
the scope of soybean 305423 9 40-3-2. As the ERA does not cover cultivation and did not identify
potential adverse environmental effects from soybean 305423 9 40-3-2, no case-speciﬁc monitoring is
necessary. The GMO Panel agrees with the reporting intervals proposed by the applicant in its PMEM
plan.
48 Dossier: Part I – Section D9.8 and D10.
49 Additional information: 3/9/2015.
50 Dossier: Part I – Section D11; additional information: 26/2/2014.
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3.7.3. Conclusion
The scope of the PMEM plan provided by the applicant and the reporting intervals are in line with
the intended uses of soybean 305423 9 40-3-2 and the GMO Panel guidelines on the PMEM of GM
plants (EFSA GMO Panel, 2011b).
4. Overall conclusions
No new data on the single soybean events 305423 and 40-3-2 that would lead to a modiﬁcation of
the original conclusions on their safety were identiﬁed.
Based on the molecular, agronomic, phenotypic and compositional characteristics, the GMO
Panel considers that the combination of soybean single events 305423 and 40-3-2 in the two-event
stack soybean 305423 9 40-3-2 did not raise concerns regarding food and feed safety or nutrition.
The combination of the newly expressed proteins in the two-event stack soybean does not raise
concerns for human and animal health.
The agronomic and phenotypic characteristics and the composition of soybean 305423 9 40-3-2
were compared under ﬁeld conditions with those of the non-GM comparator Jack and three additional
comparators (a negative segregant of soybean 305423 9 40-3-2 and the two single-event parental
lines soybean 305423 and 40-3-2), and tested for equivalence with a set of non-GM soybean reference
varieties. Soybean 305423 9 40-3-2 differs from the non-GM comparator Jack and the negative
segregant, and is not equivalent to the non-GM soybean reference varieties, in having an altered fatty
acid proﬁle. The changes in fatty acid proﬁle are consistent with those observed in the single-event
soybean 305423, including the increase in oleic acid content (the intended trait). No further
assessment for food and feed safety was needed for the other differences, or any other lack of
equivalence, identiﬁed in the agronomic and phenotypic characteristics and composition of soybean
305423 9 40-3-2. The comparison with the two parental lines (the single events soybean 305423 and
40-3-2) did not reveal any potential interaction that could be of concern for food and feed safety.
Nutritional assessment on soybean 305423 9 40-3-2 oil and oil-containing food products did not
identify concerns for human health and nutrition. The contribution to overall human exposure of fatty
acids from other soybean 305423 9 40-3-2 products would be small and is not expected to affect the
conclusion on human health and nutrition. Based on the assessment of the single event 305423, on
compositional data for soybean 305423 9 40-3-2, and on the results of a feeding study in chickens for
fattening, the GMO Panel concludes that there are no concerns regarding the use of feedingstuffs
derived from defatted toasted 305423 9 40-3-2 soybean meal.
Considering the intended altered soybean 305423 9 40-3-2 nutritional composition, a proposal for
a PMM plan needs to be provided by the applicant (EFSA GMO Panel, 2011a).
In the case of accidental release into the environment of viable seeds of soybean 305423 9 40-3-2,
there are no indications of an increased likelihood of establishment and spread of occasional feral
soybean 305423 9 40-3-2 plants, unless these plants are exposed to ALS-inhibiting or glyphosate-
based herbicides. The unlikely but theoretically possible transfer of the recombinant genes from
soybean 305423 9 40-3-2 to bacteria does not raise a safety concern for these bacteria owing to the
lack of a selective advantage. Potential interactions of soybean 305423 9 40-3-2 with the biotic and
abiotic environment were not considered a relevant issue by the GMO Panel. Therefore, considering
the introduced traits, the outcome of the comparative analysis, the routes of exposure and the limited
exposure levels, the GMO Panel concludes that soybean 305423 9 40-3-2 would not raise safety
concerns in the event of accidental release of viable GM soybean seeds into the environment. The
scope of the PMEM plan provided by the applicant and the reporting intervals are in line with the
intended uses of soybean 305423 9 40-3-2 and the GMO Panel guidelines on the PMEM of GM plants.
In conclusion, the GMO Panel considers that the information available for soybean 305423 9 40-3-2
addresses the scientiﬁc comments raised by the Member States and that soybean 305423 9 40-3-2, as
described in this application, is as safe as the non-GM comparator and non-GM conventional soybean
varieties with respect to potential effects on human and animal health and the environment in the
context of its scope.
Considering the modiﬁed composition and nutritional values of soybean 305423 9 40-3-2, the GMO
Panel agrees with the speciﬁc labelling proposal provided by the applicant, in accordance with Articles
13(2)(a) and 25(2)(c) of Regulation (EC) No 1829/2003.
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Documentation requested and provided to EFSA
1) Letter from the Competent Authority of the Netherlands received 24 September 2007
concerning a request for authorisation for the placing on the market of genetically modiﬁed
soybean 305423 9 40-3-2 for food and feed uses, import and processing submitted in
accordance with Regulation (EC) No 1829/2003 by Pioneer Overseas Corporation.
2) Acknowledgement letter dated 25 September 2007 from EFSA to the Competent Authority
of the Netherlands.
3) Letter from EFSA to applicant dated 12 November 2007 requesting additional information
under completeness check.
4) Letter from applicant to EFSA received on 20 November 2007 providing additional
information under completeness check.
5) Letter from EFSA to applicant dated 19 February 2008 delivering the ‘Statement of Validity’
for application EFSA-GMO-NL-2007-47 (soybean 305423 9 40-3-2) submitted by Pioneer
Overseas Corporation under Regulation (EC) No 1829/2003.
6) Letter from EFSA to applicant dated 29 February 2008 stopping the clock due the on-going
assessment of the single event 305423 (application reference EFSA-GMO-UK-2007-45).
7) Letter from EFSA to applicant dated 8 December 2009 requesting additional information
and maintaining the clock stopped.
8) Letter from applicant to EFSA received on 27 January 2010 providing additional
information.
9) Letter from EFSA to applicant dated 15 December 2010 maintaining the clock stopped due
to the on-going assessment of the single event 305423 (application reference EFSA-GMO-
UK-2007-45).
10) Letter from applicant to EFSA received on 5 December 2013 providing additional
information spontaneously.
11) Letter from EFSA to applicant dated 10 December 2013 re-starting the clock due to the
ﬁnalisation of the assessment of the single event 305423 (application reference EFSA-GMO-
UK-2007-45).
12) Letter from EFSA to applicant dated 13 February 2014 requesting additional information
and stopping the clock.
13) Letter from applicant to EFSA received on 26 February 2014 providing additional
information.
14) Letter from EFSA to applicant dated 1 April 2014 requesting additional information and
maintaining the clock stopped.
15) Letter from applicant to EFSA received on 22 April 2014 providing additional information.
16) Letter from EFSA to applicant dated 22 May 2014 requesting additional information and
maintaining the clock stopped.
17) Letter from applicant to EFSA received on 20 June 2014 providing additional information.
18) Letter from applicant to EFSA received on 3 July 2014 providing additional information.
19) Letter from EFSA to applicant dated 4 July 2014 requesting additional information and
maintaining the clock stopped.
20) Letter from applicant to EFSA received on 24 July 2014 providing additional information.
21) Letter from EFSA to applicant dated 25 July 2014 requesting additional information and
maintaining the clock stopped.
22) Letter from EFSA to applicant dated 4 September 2014 requesting additional information
and maintaining the clock stopped.
23) Letter from applicant to EFSA received on 9 September 2014 providing additional information.
24) Letter from applicant to EFSA received on 6 October 2014 providing additional information.
25) Letter from EFSA to applicant dated 10 November 2014 requesting additional information
and maintaining the clock stopped.
26) Letter from applicant to EFSA received on 1 December 2014 providing additional information.
27) Letter from EFSA to applicant dated 10 February 2015 requesting additional information
and maintaining the clock stopped.
28) Letter from applicant to EFSA received on 16 April 2015 providing additional information
and complementing additional information already received spontaneously.
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29) Letter from EFSA to applicant dated 21 April 2015 requesting additional information and
maintaining the clock stopped.
30) Letter from EFSA to applicant dated 5 May 2015 requesting additional information and
maintaining the clock stopped.
31) Letter from applicant to EFSA received on 13 May 2015 providing additional information.
32) Letter from applicant to EFSA received on 29 June 2015 providing additional information.
33) Letter from applicant to EFSA received on 30 July 2015 providing additional information
spontaneously.
34) Letter from applicant to EFSA received on 3 September 2015 providing clariﬁcations on the
Labelling proposal of the application.
35) Letter from EFSA to applicant dated 10 September 2015 requesting additional information
and maintaining the clock stopped.
36) Letter from applicant to EFSA received on 25 September 2015 providing additional
information.
37) Letter from EFSA to applicant dated 20 October 2015 re-starting the clock (re-start date
applicable was 14 October 2015).
38) Letter from applicant to EFSA received on 9 November 2015 providing additional
information spontaneously.
39) Letter from EFSA to applicant dated 8 December 2015 requesting additional information
and stopping the clock.
40) Letter from applicant to EFSA received on 1 February 2016 providing additional
information.
41) Letter from EFSA to applicant dated 21 April 2016 requesting additional information and
maintaining the clock stopped.
42) Letter from applicant to EFSA received on 19 May 2016 providing additional information.
43) Email from EFSA to applicant dated 20 May 2016 re-starting the clock (re-start date
applicable was 19 May 2016).
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Abbreviations
ADF acid detergent ﬁbre
AHAS acetohydroxyacid synthase
ALS acetolactate synthase
CaMV cauliﬂower mosaic virus
CHT conventional herbicide treatment
CTP chloroplast transit peptide
Dw dry weight
GMO Panel Panel on Genetically Modiﬁed Organisms of the European Food Safety Authority
ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
FA fatty acid
FAD Fatty Acid Desaturase
GM genetically modiﬁed
GMO genetically modiﬁed organism
GM-HRA Glycine max herbicide-resistant ALS
IgE immunoglobulin E
IHT intended herbicide treatment
KTi3 Kunitz trypsin inhibitor gene 3
MUFA monounsaturated fatty acids
NOS nopaline synthase
NDF neutral detergent ﬁbre
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PMEM post-market environmental monitoring
PMM post-market monitoring
PUFA polyunsaturated fatty acids
RBD reﬁned bleached deodorised
SAMS S-adenosyl-L-methionine synthetase
SFA saturated fatty acids
TFA trans fatty acids
TIU trypsin inhibitor units
UTR untranslated region
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